NZ613543B2

NZ613543B2 - Anticoagulant antidotes

Info

Publication number: NZ613543B2
Application number: NZ613543A
Authority: NZ
Inventors: Keith Canada; Robert Copenhaver; Norbert Hauel; Tobias Litzenburger; Christopher Ronald Sarko; Sanjaya Singh; Ryn Joanne Van; Alisa K Waterman
Original assignee: Boehringer Ingelheim International Gmbh
Priority date: 2011-03-30
Filing date: 2012-03-27
Publication date: 2015-11-03

Abstract

Disclosed are antibodies comprising the CDRs GYTFTDYYMH, ETNPRNGGTTYNEKFKG, GTSGYDYFDY, RSSQSIVHSDGNIYLE, KVSYRFS and FQASHVPYT.

Description

ANTICOAGULANT ANTIDOTES TECHNICAL FIELD The t ion pertains to the field of medicine, in particular to the field of anticoagulant therapy.

BACKGROUND ATION Anticoagulants are substances that prevent coagulation; that is, they stop blood from clotting. Anticoagulants are widely used in human therapy as a medication for thrombotic disorders, for example primary and secondary prevention of deep vein thrombosis, pulmonary embolism, myocardial infarctions and strokes in those who are predisposed.

An important class of oral anticoagulants acts by antagonizing the effects of vitamin K, for example the coumarins which include in. A second class of compounds t coagulation indirectly via a cofactor such as antithrombin III or heparin cofactor II. This includes l low molecular weight heparin products which catalyse the inhibition of predominantly factor Xa (and to a lesser degree thrombin) via antithrombin III (bemiparin, certoparin, dalteparin, enoxaparin, nadroparin, parnaparin, reviparin, tinzaparin), Smaller chain oligosaccharides parinux, rinux) inhibit only factor Xa via antithrombin III. Heparinoids (danaparoid, xide, dermatan sulfate) act via both cofactors and inhibit both factor Xa and thrombin. A third class represents the direct inhibitors of coagulation. Direct factor Xa inhibitors include apixaban, edoxaban, otamixaban, rivaroxaban, and direct thrombin inhibitors include the bivalent hirudins irudin, Iepirudin, desirudin), and the monovalent compounds argatroban and dabigatran.

As blood clotting is a biological mechanism to stop bleeding, a side effect of anticoagulant therapy may be unwanted bleeding events. It is therefore desirable to provide an antidote to be able to stop such anticoagulant-related ng events when they occur (Zikria and , Current Opinion in Hematology 2009, 16(5): 347-356). One way to achieve this is by neutralizing the activity of the agulant compound present in the patient after administration.

Currently available anticoagulant antidotes are protamine (for neutralization of heparin) and vitamin K for neutralization of vitamin K antagonists like warfarin. Fresh frozen plasma and recombinant factor VIIa have also been used as non-specific antidotes in patients under low molecular weight heparin treatment, suffering from major trauma or severe hage (Lauritzen, B. et al, Blood, 2005, 607A-608A.). Also reported are protamine fragments (US Patent No. 6,624,141) and small synthetic peptides (US Patent No. 6,200,955) as heparin or low molecular weight n tes; and thrombin muteins (US Patent No. 6,060,300) as antidotes for thrombin inhibitor. Prothrombin intermediates and derivatives have been reported as antidotes to n and synthetic thrombin inhibitors (US Patent Nos. 5,817,309 and 6,086,871). For direct factor Xa inhibitors, inactive factor Xa analogs have been proposed as antidotes (WO2009042962). Furthermore, recombinant factor VIIa has been used to reverse the effect of indirect antithrombin III ent factor Xa inhibitors such as fondaparinux and idraparinux (Bijsterveld, NR et al, Circulation, 2002, 106: 2550-2554; Bijsterveld, NR et al, British J. of Haematology, 2004 (124): 653-658). A review of methods of anticoagulant reversal is provided in Schulman and Bijsterveld, Transfusion Medicine Reviews 2007, 21(1): 37-48.

International patent application WO2011089183 discloses antibodies that can bind and neutralize the activity of tran.

There is a need to provide improved antidotes for anticoagulant therapy, and in particular to provide antidotes for direct thrombin inhibitors like dabigatran for which no specific antidotes have been disclosed so far.

BRIEF SUMMARY OF THE INVENTION ing to a first aspect of the invention, there is provided an antibody molecule against dabigatran comprising a heavy chain variable domain with a CDR1 of SEQ ID NO: 67, a CDR2 of SEQ ID NO: 68, and a CDR3 of SEQ ID NO: 9, and a light chain variable domain with a CDR1 of SEQ ID NO: 64, a CDR2 of SEQ ID NO: 65, and a CDR3 of SEQ ID NO: 69.

According to a second aspect of the ion, there is provided use of an antibody molecule according to the first aspect of the ion for the manufacture of a medicament for the therapy or tion of side effects of agulant therapy, and/or for reversal of an overdosing of an agulant.

According to a third aspect of the invention, there is provided a method of manufacturing an antibody molecule according to the first aspect of the invention, comprising AH26(10039265_1):JIN (a) providing a host cell comprising one or more nucleic acids encoding said antibody molecule in functional association with an expression control sequence, (b) cultivating said host cell, and (c) recovering the antibody molecule from the cell culture, wherein the host cell is not within a human.

According to a fourth aspect of the invention, there is provided a kit comprising an antibody according to the first aspect of the invention, or a pharmaceutical composition thereof.

According to a fifth aspect of the invention, there is provided a kit comprising: (a) an antibody according to the first aspect of the invention, or a pharmaceutical composition thereof; (b) a ner; and (c) a label.

According to a sixth aspect of the invention, there is provided a kit comprising an dy according to the first aspect of the ion, and dabigatran, dabigatran etexilate, a prodrug of dabigatran or a pharmaceutically acceptable salt thereof.

In a further aspect, the present invention s to an antibody molecule capable of neutralizing the ty of an agulant.

In a further aspect, the antibody molecule has binding specificity for the anticoagulant.

In a further aspect, the anticoagulant is a direct thrombin inhibitor, a Factor Xa inhibitor, or a n K antagonist.

AH26(10039265_1):JIN In a further aspect, the anticoagulant is dabigatran, argatroban, melagatran, ximelagatran, hirudin, bivalirudin, lepirudin, desirudin, apixaban, otamixaban, edoxaban, rivaroxaban, defibrotide, ramatroban, antithrombin III, or drotrecogin alpha.

In another aspect, the present invention relates to an antibody molecule against dabigatran, dabigatran exetilate, and/or an O-acylglucuronide of dabigatran.

In a further aspect, the present invention relates to an antibody molecule against dabigatran, tran exetilate, and/or an glucuronide of dabigatran with reduced immunogenicity in man.

In a further aspect, the present invention relates to an antibody molecule against dabigatran, dabigatran ate, and/or an O-acylglucuronide of dabigatran with improved physicochemical properties, in particular improved solubility in aqueous solvents.

In a further aspect, the present ion relates to an antibody molecule against dabigatran, dabigatran exetilate, and/or an O-acylglucuronide of dabigatran with improved produceability in host cells, in particular resulting in ed production yields.

In a r aspect, the antibody le is a polyclonal antibody, a monoclonal dy, a human antibody, a humanized antibody, a chimeric dy, a fragment of an antibody, in ular a Fab, Fab’, or F(ab’)2 fragment, a single chain antibody, in particular a single chain le nt (scFv), a domain antibody, a nanobody, a diabody, or a DARPin.

In a further aspect, the present invention relates to an dy molecule as described above for use in ne.

In a further aspect, the present invention relates to an antibody molecule as described above for use in the therapy or prevention of side effects of anticoagulant therapy.

In a further aspect, the side effect is a bleeding event.

In a further aspect, the present invention relates to a method of treatment or prevention of side effects of anticoagulant therapy, comprising administering an effective amount of an dy molecule as described above to a patient in need thereof.

In another aspect, the present invention relates to a kit comprising an antibody molecule as described, together with a ner and a label.

BRIEF DESCRIPTION OF THE DRAWINGS Figure 1: Increased time to clotting seen with increased concentrations of dabigatran using the thrombin clotting time assay. The 200 nM concentration resulted in an d elevation in ng time over baseline and was used in the first and second set of experiments. The 500 nM tration (supratherapeutic) was used in the last set of experiments.

Figure 2: Four different antibodies to dabigatran (A-D) all lized the prolonged clotting time of dabigatran in human plasma. Baseline clotting in human plasma was 10.9 seconds, when 200 nM dabigatran was preincubated with plasma, ng was ged to 51 seconds. Each antibody was added to plasma preincubated with 200 nM of dabigatran and further ted for 5 min. The thrombin clotting time was then initiated by addition of thrombin. Each antibody could reverse the clotting time of dabigatran to different degrees. The most concentrated solution resulted in the largest reversal of anticoagulant activity.

Figure 3: The effect of sing trations of polyclonal antibody (antibody D) added to human plasma that had been preincubated with 200 nM dabigatran was measured. Baseline clotting time was 11 seconds, addition of dabigatran prolonged clotting to 63.7 seconds. The effect of increasing dilutions of antibody on reversing the prolonged thrombin clotting time with tran was then tested. The lowest concentration reduced the thrombin clotting time to 43.9 seconds. Higher concentrations completely reduced the thrombin clotting time to baseline levels and resulted in complete neutralization of the anticoagulant effect of dabigatran. on of a non specific rabbit WO 30834 polyclonal antibody (square) had no effect on reversing the anticoagulant effect of dabigatran.

Figure 4: The effect of increasing concentrations of polyclonal antibody (antibody D) added to human plasma that had been preincubated with 500 nM dabigatran was measured. Baseline clotting time was 10.9 seconds, addition of this higher concentration of dabigatran prolonged clotting to 111.7 seconds old se). The effect of a 1:2 dilution of antibody or stock solution reversed the prolonged thrombin clotting time with dabigatran in a concentration dependent manner. The highest concentration also 1O completely reversed the in clotting time to baseline levels and resulted in complete neutralization of the anticoagulant effect of even supratherapeutic concentrations of dabigatran.

Figure 5: A mouse monoclonal antibody (Clone 22) reverses the anticoagulant effect of dabigatran in human plasma and in human whole blood. lncreasing concentrations of mouse antibody were added to human plasma or whole blood that had been preincubated with 30 nM dabigatran. The assay was initiated by the addition of 1.5 — 2 U/mL of thrombin and clotting time was measured. 100% dabigatran activity was defined as the difference in clotting time in the presence and absence of compound. The dy dose ently inhibited the tran mediated prolongation of clotting time.

Figure 6: A mouse Fab generated from the Clone 22 antibody es the anticoagulant effect of dabigatran in human . Increasing concentrations of mouse Fab were added to human plasma that had been preincubated with 7 nM dabigatran. The intact antibody was also tested as a positive control. The assay was initiated by the additon of 0.4 U/mL of thrombin and clotting time was ed. 100% inhibition was defined as the complete block of the dabigatran mediated increase in clotting time. The Fab dose dependently inhibited the tran induced prolongation in clotting time in human plasma.

Figure 7: A mouse monoclonal dy (Clone 22) reverses the anticoagulant effect of dabigatran ucuronide in human plasma. Increasing concentrations of mouse antibody were added to human plasma that had been preincubated with 7 nM of dabigatran acylglucuronide or dabigatran. The assay was initiated by the additon of 0.4 U/mL of in and ng time was measured. 100% inhibition was defined as the complete block of the compound mediated increase in clotting time. The antibody dose dependently inhibited the dabigatran acylglucuronide induced prolongation in clotting time in human plasma.

Figure 8: Selected chimeric antibodies t dabigatran activity in the thrombin clotting time assay. Increasing concentrations of antibody were added to human plasma that had been preincubated with 7 nM dabigatran. The intact antibody was also tested as a positive control. The assay was initiated by the additon of 0.4 U/mL of thrombin and clotting time was measured. 100% inhibition was defined as the complete block of the tran ed increase in clotting time. The antibodies dose dependently inhibited the dabigatran induced prolongation in ng time in human plasma.

Figure 9: Fab VH5c/Vk18 (SEQ ID NO: 99 and SEQ ID NO: 100) and VH5c/Vk21 (SEQ ID NO: 99 and SEQ ID NO: 101) inhibit dabigatran activity in the thrombin clotting time plasma assay. The assay was performed as described above.

Figure 10: Fab VH5c/Vk18 (SEQ ID NO: 99 and SEQ ID NO: 100) and k21 (SEQ ID NO: 99 and SEQ ID NO: 101) inhibit dabigatran activity in the plasma and whole blood thrombin clotting time assay. The assay was performed as bed above.

Figure 11: l structure of the Fab-Dabigatran complexes. A: Crystal structure of Fab 18/15 (W02011089183) in complex with dabigatran. B: Crystal structure of Fab VH5c/Vk18 (SEQ ID NO: 99 and SEQ ID NO: 100) in complex with dabigatran. C: Conformation of dabigatran as seen in the crystal structure with Fab 18/15. D: Extended mation of dabigatran as seen in the crystal structure with VH5c/Vk18.

Figure 12: Spatial aggregation propensities (SAP) calculated for (A) Fab 18/15 (B) Fab VH5c/Vk18 and (C) Fab VH5c/Vk21 comprising the CDRs (left panels) or the whole Fv region (right panels).

Figure 13: Titers of (A) Fab 18/15 (B) Fab VH5c/Vk18 and (C) Fab VH5c/Vk21 from fed batch runs of CHO cells transfected with corresponding Fab sion constructs.

DETAILED DESCRIPTION OF THE INVENTION In one aspect, the t invention relates to an antibody molecule capable of neutralizing the activity of an anticoagulant.

Antibodies (also known as immunoglobulins, abbreviated lg) are gamma globulin proteins that can be found in blood or other bodily fluids of vertebrates, and are used by the immune system to fy and neutralize foreign objects, such as bacteria and viruses.

They are typically made of basic structural units - each with two large heavy chains and two small light chains - to form, for example, monomers with one unit, dimers with two units or pentamers with five units. Antibodies can bind, by non-covalent interaction, to other molecules or structures known as antigens. This binding is specific in the sense that an antibody will only bind to a specific structure with high affinity. The unique part of the antigen ized by an dy is called an epitope, or antigenic determinant. The part of the antibody binding to the epitope is sometimes called paratope and resides in the so- called variable , or variable region (Fv) of the antibody. The variable domain comprises three so-called complementary-determining region (CDR’s) spaced apart by framework regions (FR’s).

Vlﬁthin the t of this invention, reference to CDR’s is based on the definition of Chothia (Chothia and Lesk, J. Mol. Biol. 1987, 196: 901—917), together with Kabat ( E.A.

Kabat, T.T. Wu, H. Bilofsky, M. Reid-Miller and H. Perry, Sequence of Proteins of Immunological lnterest, National Institutes of Health, Bethesda (1983)).

The art has further developed antibodies and made them ile tools in medicine and technology. Thus, in the context of the present invention the terms “antibody molecule” or ody” (used mously herein) do not only include antibodies as they may be found in , sing e.g. two light chains and two heavy chains, orjust two heavy chains as in camelid species, but furthermore encompasses all molecules sing at least one paratope with binding specificity to an antigen and structural similarity to a variable domain of an immunoglobulin.

Thus, an antibody molecule according to the invention may be a polyclonal antibody, a monoclonal antibody, a human antibody, a humanized antibody, a chimeric antibody, a fragment of an antibody, in particular a Fv, Fab, Fab’, or F(ab’)2 fragment, a single chain antibody, in ular a single chain variable nt , a Small r lmmunopharmaceutical (SMIP), a domain antibody, a nanobody, a diabody.

Polyclonal dies represent a collection of antibody molecules with different amino acid sequences and may be obtained from the blood of vertebrates after immunization with the antigen by processes well-known in the art.

Monoclonal antibodies (mAb or moAb) are monospecific antibodies that are identical in 1O amino acid sequence. They may be produced by hybridoma technology from a hybrid cell line (called hybridoma) representing a clone of a fusion of a ic antibody-producing B cell with a myeloma (B cell cancer) cell (Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of ined specificity. Nature 1975;256:495-7.) atively, monoclonal antibodies may be produced by recombinant expression in host cells (Norderhaug L, n T, Michaelsen TE, Sandlie |. (May 1997). "Versatile vectors for transient and stable expression of recombinant antibody molecules in mammalian cells.".

J lmmunol Methods 204 (1): 77—87; see also below).

For application in man, it is often desirable to reduce immunogenicity of antibodies originally derived from other species, like mouse. This can be done by construction of ic antibodies, or by a process called “humanization”. In this context, a “chimeric antibody” is understood to be an antibody comprising a sequence part (e.g. a variable domain) derived from one species (e.g. mouse) fused to a sequence part (e.g. the constant domains) derived from a different species (e.g. human). A “humanized antibody” is an dy sing a variable domain originally derived from a non-human species, wherein certain amino acids have been mutated to resemble the overall sequence of that variable domain more closely to a sequence of a human variable domain. Methods of chimerisation and -humanization of antibodies are well-known in the art (Billetta R, Lobuglio AF. “Chimeric antibodies”. Int Rev l. 1993;10(2—3):165-76; Riechmann L, Clark M, Waldmann H, Winter G (1988). "Reshaping human antibodies for therapy".

Nature: 332:323.) Furthermore, technologies have been ped for creating antibodies based on sequences derived from the human genome, for example by phage display or using enic animals (VVO 90/05144; D. Marks, H.R. Hoogenboom, T.P. Bonnert, J.

McCafferty, A.D. Griffiths and G. Winter (1991) "By-passing immunisation. Human antibodies from V-gene libraries displayed on phage." J.Mol.Biol., 222, 7; Knappik et al., J. Mol. Biol. 296: 57-86, 2000; 8. Carmen and L. Jermutus, "Concepts in antibody phage display". Briefings in Functional Genomics and Proteomics 2002 1(2):189-203; Lonberg N, Huszar D. "Human antibodies from transgenic mice". Int Rev lmmunol. 1995;13(1):65-93.; Briiggemann M, Taussig MJ. "Production of human antibody oires in transgenic mice”. Curr Opin Biotechnol. 1997 Aug;8(4):455-8.). Such antibodies are “human antibodies” in the context of the present invention.

Antibody molecules according to the present invention also e fragments of immunoglobulins which retain antigen binding properties, like Fab, Fab’, or F(ab’)2 fragments. Such fragments may be obtained by fragmentation of immunoglobulins e.g. by proteolytic digestion, or by recombinant expression of such fragments. For example, immunoglobulin digestion can be accomplished by means of routine techniques, e.g. using papain or pepsin (VVO 94/29348), or endoproteinase Lys-C (Kleemann, et al, Anal.

Chem. 80, 2001-2009, 2008). Papain or Lys-C digestion of antibodies typically produces two cal antigen binding fragments, so-called Fab fragments, each with a single n binding site, and a residual Fc fragment. Pepsin treatment yields an F(ab')2.

Methods of producing Fab molecules by recombinant expression in host cells are outlined in more detail below.

A number of technologies have been developed for placing variable domains of immunoglobulins, or molecules derived from such variable domains, in a different lar t. Those should be also considered as “antibody les” in accordance with the present invention. In general, these antibody molecules are r in size compared to immunoglobulins, and may comprise a single amino acid chain or be composed of several amino acid chains. For example, a single-chain variable fragment (scFv) is a fusion of the variable s of the heavy and light chains of immunoglobulins, linked er with a short , usually serine (S) or glycine (G) (WO 49; WO 91/17271; Huston et al; International Reviews of Immunology, Volume 10, 1993, 195 - 217). e domain antibodies” or ,,nanobodies” harbour an antigen-binding site in a single lg-like domain (WO 94/04678; WO 03/050531, Ward et al., Nature. 1989 Oct 12;341(6242):544-6; Revets et al., Expert Opin Biol Ther. 5(1):111-24, 2005). One or WO 30834 more single domain antibodies with binding specificity for the same or a different antigen may be linked together. Diabodies are bivalent antibody molecules consisting of two amino acid chains comprising two variable domains (WO 04, Holliger et al., Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6444-8). Other examples for antibody-like molecules are immunoglobulin super family antibodies (lgSF; Srinivasan and Roeske, t Protein Pept. Sci. 2005, 6(2): 185-96). A ent concept leads to the so-called Small Modular lmmunopharmaceutical (SMIP) which comprises a Fv domain linked to single-chain hinge and effector domains devoid of the constant domain CH1 (WO 02/056910).

In a further aspect, an antibody molecule of the invention may even only have remote structural relatedness to an immunoglobulin variable domain, or no such relation at all, as long as it has a certain binding specificity and affinity comparable to an immunoglobulin variable domain. Such munoglobulin “antibody ”, sometimes called “scaffold proteins”, may be based on the genes of protein A, the lipocalins, a fibronectin domain, an ankyrin consensus repeat domain, and doxin (Skerra, Current Opinion in Biotechnology 2007, 18(4): 295-304). A preferred embodiment in the context of the present ion are designed ankyrin repeat proteins (DARPin’s; r et al., J Mol Biol. 2008 Oct 24;382(5): 1211-27; Stumpp MT, Amstutz P. Curr Opin Drug Discov Devel. 2007 Mar;10(2):153-9).

The dy molecule may be fused (as a fusion protein) or othenNise linked (by covalent or non-covalent bonds) to other molecular entities having a desired impact on the properties of the antibody molecule. For example, it may be desirable to improve pharmacokinetic properties of antibody molecules, stability e.g. in body fluids such as blood, in particular in the case of single chain antibodies or domain antibodies. A number of technologies have been developed in this regard, in ular to g half-life of such antibody molecules in the circulation, such as pegylation (WO 71; WO 98/48837; WO 2004081026), fusing or othenNise covalently attaching the antibody molecule to another antibody molecule having affinity to a serum protein like albumin (VVO 2004041865; WO 2004003019), or expression of the antibody molecule as fusion protein with all or part of a serum protein like albumin or transferrin (WO 01/79258). 2012/055397 In a further aspect, the antibody molecule has binding specificity for the anticoagulant.

“Binding specificity” means that the antibody molecule has a significantly higher binding affinity to the anticoagulant than to urally ted molecules. ty is the interaction between a single n-binding site on an antibody molecule and a single epitope. It is sed by the association constant KA = kass/kdiss, or the dissociation constant KD = kdiss/kass .

In one aspect of the invention, the antibody binds to the agulant with an affinity, as 1O determined e.g. by e plasmon resonance analysis (Malmqvist M., "Surface plasmon resonance for detection and measurement of antibody-antigen affinity and kinetics.", Curr Opin lmmunol. 1993 2):282-6.), with a KD value ranging from 0.1 pM to 100 uM, preferably 1 pM to 100 uM, preferably 1 pM to 1 uM. Antibody affinity can also be measured using kinetic exclusion assay (KinExA) technology (Darling, R.J., and Brault P- A., ic exclusion assay technology: Characterization of Molecular Interactions.” ASSAY and Drug Development Technologies. 2004, Dec 2(6): 647-657).

The binding affinity of an antibody le may be enhanced by a process known as ty maturation (Marks et al., 1992, Biotechnology 10:779-783; Barbas, et al., 1994, Proc. Nat. Acad. Sci, USA 91:3809-3813; Shier et al., 1995, Gene 169:147-155). Affinity matured dies are therefore also embraced in the present invention.

In a further aspect of the invention, the antibody molecule is capable of neutralizing the activity of the anticoagulant. That is, upon binding to the antibody molecule, the anticoagulant is no longer able to exert its anticoagulant ty, or exerts this activity at a significantly decreased magnitude. Preferably, the anticoagulant activity is decreased at least 2fold, 5fold, 10fold, or 100fold upon antibody binding, as determined in an activity assay which is appropriate for the anticoagulant at issue, particularly a clotting assay that is ive to thrombin, such as the ecarin clotting time or the thrombin clotting time (H.

Bounameaux, Marbet GA, Lammle B, et al. “Monitoring of heparin treatment. Comparison of thrombin time, activated partial thromboplastin time, and plasma heparin concentration, and analysis of the behaviour of antithrombin III”. American Journal of Clinical Pathology 1980 74(1): 68-72).

For manufacturing the antibody molecules of the invention, the skilled artisan may choose from a variety of methods well known in the art (Norderhaug et al., J lmmunol Methods 1997, 204 (1): 77—87; Kipriyanow and Le Gall, Molecular Biotechnology 26: 39- 60, 2004; Shukla et al., 2007, J. Chromatography B, 848(1): 28-39).

Anticoagulants are well-known in the art, as outlined above. In a further aspect of the invention, the anticoagulant is a direct thrombin inhibitor, a Factor Xa tor, or a vitamin K antagonist. Examples of vitamin K antagonists are the coumarins, which include warfarin. es of indirect predominantly factor Xa tors are the n group of 1O substances acting through activation of antithrombin III including several low molecular weight heparin ts (bemiparin, certoparin, dalteparin, enoxaparin, nadroparin, parnaparin, reviparin, tinzaparin), certain oligosaccharides (fondaparinux, idraparinux), heparinoids (danaparoid, sulodexide, dermatan sulfate), and the direct factor Xa inhibitors (apixaban, otamixaban, rivaroxaban). Examples of thrombin inhibitors include the bivalent hirudins (bivalirudin, lepirudin, desirudin), and the monovalent nds argatroban and dabigatran.

Thus, in a r aspect, the agulant is dabigatran, argatroban, tran, ximelagatran, hirudin, bivalirudin, lepirudin, desirudin, apixaban, edoxaban, otamixaban, rivaroxaban, defibrotide, ramatroban, antithrombin III, or drotrecogin alpha.

A red anticoagulant in the context of the present invention is dabigatran (CA8 2119141, N-[2-(4-Amidinophenylaminomethyl)methyl-1H-benzimidazol ylcarbonyl]-N-(2-pyridyl)-beta-alanine) having the chemical formula (II): (EH3 NH2 0com N HOW\0N 0 N / (II) Dabigatran is known from WO 98/37075, which discloses compounds with a thrombininhibiting effect and the effect of prolonging the thrombin time, under the name yl- 2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazolyl-carboxylic acid-N-(2-pyridyl)-N- (2-hydroxycarbonylethyl)-amide. See also Hauel et al. J Med Chem 2002, 45 (9): 1757— Dabigatran is applied as a prodrug of formula (III): C|3H3 NH N AW YN o 0 CH3 0 N EtOW\ON \ ( I” ) O N / The compound of formula III (named dabigatran etexilate, CAS 2119159; ethyl 3-[(2- {[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}methyl-1H- benzimidazolecarbonyl)-pyridinyl-amino]-propionate) is converted into the active compound (II) after entering the body. A preferred polymorph of dabigatran etexilate is dabigatran etexilate mesylate.

The main indications for dabigatran are the post-operative prevention of deep-vein thrombosis, the ent of established deep vein thrombosis and the prevention of strokes in patients with atrial fibrillation son et al., Lancet 2007, 370 (9591): 949—56; an S et al, N Engl J Med 2009, 361 (24): 2342-52; Connolly S et al., N Engl J Med 2009, 361 (12): 1139—51; Wallentin et al., Lancet 2010, 376 (9745): 3).

In the human body, glucuronidation of the carboxylate moiety is the major human metabolic pathway of dabigatran (Ebner et al., Drug Metab. Dispos. 2010, 38(9):1567-75).

It results in the formation of the 1-O-acylglucuronide (beta anomer). The 1 acylglucuronide, in on to minor ysis to the aglycon, may undergo ymatic acyl migration in aqueous on, resulting in the formation of the 2-O-, 3- O-, and ylglucuronides. Experiments with the purified 1-O-acylglucuronide and its isomeric rearrangement products revealed equipotent prolongation of the activated partial thromboplastin time compared with dabigatran.

In another aspect of the invention, the dy molecule binds both to dabigatran and dabigatran etexilate.

In another aspect of the ion, the dy molecule binds both to dabigatran and O- 1O acylglucuronides of dabigatran, in particular the 1-O-acylglucuronide of dabigatran.

In another aspect of the invention, the antibody molecule binds rmore to the 2-O-, 3- O-, and 4-O-acylglucuronides of dabigatran.

In another aspect of the invention, the antibody molecule is capable of neutralizing the activity of dabigatran and O-acylglucuronides of dabigatran, in particular the 1 acylglucuronide of dabigatran.

In the following, references to SEQ ID NOs. referto the sequences of Table 1 and the sequence listing which is part of this ation, unless indicated othenNise.

In another aspect of the invention, the antibody molecule has binding specificity for tran and comprises a heavy chain variable domain with a CDR1 selected from the group consisting of SEQ ID NO: 1, 7, 13, 19, 25, 31, 37, 43, 49, 55, 61, and 67, a CDR2 selected from the group consisting of SEQ ID NO: 2, 8, 14, 20, 26, 32, 38, 44, 50, 56, 62, and 68, and a CDR3 selected from the group consisting of SEQ ID NO: 3, 9, 15, 21, 27, 33, 39, 45, 51, 57, and 63, and a light chain variable domain with a CDR1 selected from the group consisting of SEQ ID NO: 4, 10, 16, 22, 28, 34, 40, 46, 52, 58, and 64, a CDR2 selected from the group ting of SEQ ID NO: 5, 11, 17, 23, 29, 35, 41, 47, 53, 59, and 65, and a CDR3 selected from the group consisting of SEQ ID NO: 6, 12, 18, 24, 30, 36, 42, 48, 54, 60, 66, and 69.

In another aspect of the invention, the antibody molecule has binding specificity for dabigatran and comprises a heavy chain variable domain with a CDR1 of SEQ ID NO: 1, a CDR2 of SEQ ID NO: 2, and a CDR3 of SEQ ID NO: 3, and a light chain variable domain with a CDR1 of SEQ ID NO: 4, a CDR2 of SEQ ID NO: 5, and a CDR3 of SEQ ID NO: 6.

In r aspect of the invention, the antibody molecule has binding specificity for dabigatran and comprises a heavy chain variable domain with a CDR1 of SEQ ID NO: 7, a CDR2 of SEQ ID NO: 8, and a CDR3 of SEQ ID NO: 9, and a light chain variable domain with a CDR1 of SEQ ID NO: 10, a CDR2 of SEQ ID NO: 11, and a CDR3 of SEQ ID NO: 12.

In another aspect of the invention, the antibody molecule has binding icity for dabigatran and comprises a heavy chain variable domain with a CDR1 of SEQ ID NO: 13, a CDR2 of SEQ ID NO: 14, and a CDR3 of SEQ ID NO: 15, and a light chain variable domain with a CDR1 of SEQ ID NO: 16, a CDR2 of SEQ ID NO: 17, and a CDR3 of SEQ ID NO: 18.

In another aspect of the invention, the antibody le has binding specificity for dabigatran and comprises a heavy chain variable domain with a CDR1 of SEQ ID NO: 19, a CDR2 of SEQ ID NO: 20, and a CDR3 of SEQ ID NO: 21, and a light chain variable domain with a CDR1 of SEQ ID NO: 22, a CDR2 of SEQ ID NO: 23, and a CDR3 of SEQ ID NO: 24.

In another aspect of the invention, the dy molecule has binding specificity for dabigatran and comprises a heavy chain variable domain with a CDR1 of SEQ ID NO: 25, a CDR2 of SEQ ID NO: 26, and a CDR3 of SEQ ID NO: 27, and a light chain variable domain with a CDR1 of SEQ ID NO: 28, a CDR2 of SEQ ID NO: 29, and a CDR3 of SEQ ID NO: 30.

In another aspect of the invention, the antibody molecule has binding icity for dabigatran and comprises a heavy chain variable domain with a CDR1 of SEQ ID NO: 31, a CDR2 of SEQ ID NO: 32, and a CDR3 of SEQ ID NO: 33, and a light chain variable domain with a CDR1 of SEQ ID NO: 34, a CDR2 of SEQ ID NO: 35, and a CDR3 of SEQ ID NO: 36.

In another aspect of the ion, the antibody le has binding specificity for dabigatran and comprises a heavy chain variable domain with a CDR1 of SEQ ID NO: 37, a CDR2 of SEQ ID NO: 38, and a CDR3 of SEQ ID NO: 39, and a light chain variable domain with a CDR1 of SEQ ID NO: 40, a CDR2 of SEQ ID NO: 41, and a CDR3 of SEQ ID NO: 42.

In r aspect of the invention, the antibody molecule has binding specificity for dabigatran and ses a heavy chain variable domain with a CDR1 of SEQ ID NO: 43, a CDR2 of SEQ ID NO: 44, and a CDR3 of SEQ ID NO: 45, and a light chain variable domain with a CDR1 of SEQ ID NO: 46, a CDR2 of SEQ ID NO: 47, and a CDR3 of SEQ ID NO: 48.

In another aspect of the invention, the antibody molecule has binding specificity for dabigatran and comprises a heavy chain variable domain with a CDR1 of SEQ ID NO: 49, a CDR2 of SEQ ID NO: 50, and a CDR3 of SEQ ID NO: 51, and a light chain variable domain with a CDR1 of SEQ ID NO: 52, a CDR2 of SEQ ID NO: 53, and a CDR3 of SEQ ID NO: 54.

In another aspect of the invention, the antibody molecule has binding specificity for dabigatran and comprises a heavy chain variable domain with a CDR1 of SEQ ID NO: 55, a CDR2 of SEQ ID NO: 56, and a CDR3 of SEQ ID NO: 57, and a light chain variable domain with a CDR1 of SEQ ID NO: 58, a CDR2 of SEQ ID NO: 59, and a CDR3 of SEQ ID NO: 60.

In another aspect of the invention, the antibody molecule has g specificity for dabigatran and comprises a heavy chain variable domain with a CDR1 of SEQ ID NO: 61, a CDR2 of SEQ ID NO: 62, and a CDR3 of SEQ ID NO: 63, and a light chain variable domain with a CDR1 of SEQ ID NO: 64, a CDR2 of SEQ ID NO: 65, and a CDR3 of SEQ ID NO: 66.

In another aspect of the invention, the antibody molecule has binding icity for dabigatran and comprises a heavy chain variable domain with a CDR1 of SEQ ID NO: 67, a CDR2 of SEQ ID NO: 68, and a CDR3 of SEQ ID NO: 9, and a light chain variable WO 30834 domain with a CDR1 of SEQ ID NO: 64, a CDR2 of SEQ ID NO: 65, and a CDR3 of SEQ ID NO: 69.

In another aspect of the invention, the antibody molecule comprises a heavy chain variable domain of SEQ ID NO: 70, and a light chain variable domain of SEQ ID No: 71.

In another aspect of the invention, the antibody molecule comprises a heavy chain variable domain of SEQ ID NO: 72, and a light chain variable domain of SEQ ID No: 73.

In another aspect of the invention, the antibody molecule comprises a heavy chain le domain of SEQ ID NO: 74, and a light chain variable domain of SEQ ID No: 75.

In another aspect of the invention, the antibody molecule ses a heavy chain variable domain of SEQ ID NO: 76, and a light chain variable domain of SEQ ID No: 77.

In another aspect of the invention, the antibody molecule comprises a heavy chain variable domain of SEQ ID NO: 78, and a light chain variable domain of SEQ ID No: 79.

In another aspect of the invention, the dy molecule comprises a heavy chain variable domain of SEQ ID NO: 80, and a light chain variable domain of SEQ ID No: 81.

In r aspect of the invention, the antibody molecule comprises a heavy chain variable domain of SEQ ID NO: 82, and a light chain variable domain of SEQ ID No: 83.

In another aspect of the invention, the antibody molecule comprises a heavy chain variable domain of SEQ ID NO: 84, and a light chain variable domain of SEQ ID No: 85.

In another aspect of the ion, the antibody molecule comprises a heavy chain variable domain of SEQ ID NO: 86, and a light chain variable domain of SEQ ID No: 87.

In another aspect of the invention, the antibody molecule comprises a heavy chain le domain of SEQ ID NO: 88, and a light chain variable domain of SEQ ID No: 89.

In another aspect of the invention, the antibody molecule comprises a heavy chain variable domain of SEQ ID NO: 90, and a light chain variable domain of SEQ ID No: 91.

In another aspect of the invention, the dy molecule comprises a heavy chain variable domain of SEQ ID NO: 92, and a light chain le domain of SEQ ID No: 93.

In another aspect of the invention, the antibody le comprises a heavy chain variable domain of SEQ ID NO: 92, and a light chain le domain of SEQ ID No: 94. 1O In another aspect of the invention, any one of the aforementioned light chain variable s is fused to a constant domain of SEQ ID NO: 97.

In another aspect of the invention, any one of the aforementioned heavy chain variable domains is fused to a constant domain of SEQ ID NO: 98.

In another aspect of the invention, the antibody molecule comprises a heavy chain of SEQ ID NO: 95, and a light chain of SEQ ID No: 96.

In certain aspects, the invention concerns antibodies against dabigatran which have a high solubility in aqeous media and a low tendency of aggregation.

In another aspect of the invention, the antibody molecule is a scFv le. In this format, the variable domains disclosed herein may be fused to each other with a suitable linker peptide. The construct may comprise these elements in the order, from N terminus to C terminus, (heavy chain variable domain)-(Iinker peptide)-(Iight chain variable domain), or (light chain le )-(Iinker peptide)-( heavy chain variable domain).

Processes are known in the art which allow inant expression of nucleic acids encoding st constructs in host cells (like E. coli, Pichia pastoris, or mammalian cell lines, e.g. CHO or NSO), yielding functional scFv molecules (see e.g. Rippmann et al., Applied and Environmental Microbiology 1998, 64(12): 4862-4869; Yamawaki et al., J. Biosci.

Bioeng. 2007, 104(5): 403-407; Sonoda et al., Protein Expr. Purif. 2010, 70(2): 248-253).

In particular, the scFv antibody les of the invention can be produced as follows.

The constructs can be expressed in different E. coli strains like W3110, TG1, BL21, BL21(DE3), HMS174, HMS174(DE3), MM294 under control of an inducible promoter. This promoter can be chosen from lacUV5, tac, T7, trp, trc, T5, araB. The cultivation media are preferably fully defined according to Wilms et al., 2001 (Wilms et al., Biotechnology and ineering 2001, 73(2): 95-103) DeLisa et al., 1999 (DeLisa et al., Biotechnology and Bioengineering 1999, 65(1): 54-64) or equivalent. However, supplementation of the batch medium and / or feed medium with amino acids such as isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan and valin or x media components 1O such as soy peptone or yeast extract may be beneficial. The process for tation is performed in a fed-batch mode. Conditions: Temperature 20 — 40 °C, pH 5.5 — 7.5, D0 is kept above 20%. After consumption of the initial carbon source the culture is fed with the feed media stated above (or equivalent). When a dry cell weight of 40 to 100 g/L is reached in the fermenter the culture is induced with an appropriate inducer corresponding to the used promoter system (e.g. IPTG, lactose, arabinose). The induction can either be performed as a pulsed full induction or as a partial induction by g the respective inducer into the fermenter over a prolonged time or a combination thereof. The tion phase should last 4 hours at least. The cells are recovered by centrifugation in bowl centrifuges, tubular bowl centrifuges or disc stack centrifuges, the culture supernatant is discarded.

The E. coli cell mass is resuspended in 4- to 8—fold amount of lysis buffer (phosphate or Tris , pH 7-8.5). Cell lysis is preferably performed by high pressure homogenization followed by ry of the pellet by centrifugation in bowl, tubular bowl or disc stack fuges. Pellet containing scFv inclusion bodies is washed 2-3 times with 20 mM Tris, 150 mM NaCl, 5 mM EDTA, 2 M Urea, 0.5% Triton X—100, pH 8.0 followed by two wash steps using 20 mM Tris, 150 mM NaCl, 5 mM EDTA, pH 8.0. scFv inclusion bodies are finally recovered by centrifugation in bowl, tubular bowl or disc stack centrifuges.

Solubilisation of scFv inclusion bodies can be performed in 100 mM Glycine/NaOH, 5 mM EDTA, 20 mM dithiothreitol, pH 9.5-10.5 containing chaotropic agents such as 6 M Guanidine-HCI or 8—10 mM Urea. After incubation for 30-60 minutes on is centrifuged and supernatant containing the target protein red for uent refolding. ing is preferably performed in fed batch mode by diluting the protein solution 1:10- 1:50 in refolding buffer to a final protein concentration of 0.1-0.5 mg/ml. Refolding buffer can contain 50-100 mM Tris and/or 50-100 mM Glycine, 50-150 mM NaCI, 1-3 M urea, 0.5-1 M ne, 2-6 mM of redox system such as e.g. / cystine or oxidized/reduced glutathione, pH 9.5-10.5. After incubation for 24-72 h at 4°C refolding solution is optionally filtrated using a 0.22 pm filter, diluted and pH adjusted to pH 0. Protein is separated via cation ge chromatography in binding mode (e.g. arl p S-650M, SP Sepharose FF or S HyperCelTM) at pH 7.0-8.5. Elution is performed by a linear increasing NaCI gradient. Fractions containing the target protein are pooled and subsequently separated on anion exchange column in non-binding mode (e.g. Toyopearl GigaCap Q-650M, Q-Sepharose FF, Q HyperCelTM) followed by a cation exchange polishing step (eg. SP Sepharose HP). Fractions containing the target protein with a purity level of minimally 90% are pooled and formulated by diafiltration or size exclusion chromatography in PBS. Identity and product quality of the produced scFv molecule are analysed by reducing SDS-PAGE where the scFv can be detected in one major band of approx. 26 kDa. r assays for characterization of the scFv include mass ometry, RP-HPLC and SE-HPLC.

In another aspect of the invention, the antibody molecule is a Fab molecule. In that format, the variable domains disclosed above may each be fused to an immunoglobulin constant domain, preferably of human origin. Thus, the heavy chain variable domain may be fused to a CH1 domain (a so-called Fd nt), and the light chain variable domain may be fused to a CL domain.

In another aspect of the ion, the antibody molecule ses a heavy chain of SEQ ID NO: 99, and a light chain of SEQ ID No: 100. Preferably, the antibody molecule is a Fab molecule.

In another aspect of the invention, the antibody molecule comprises a heavy chain of SEQ ID NO: 99, and a light chain of SEQ ID No: 101. Preferably, the antibody molecule is a Fab molecule.

In another aspect of the invention, the antibody molecule is a Fab molecule which consists of a heavy chain of SEQ ID NO: 99, and a light chain of SEQ ID No: 100.

In another aspect of the invention, the antibody molecule is a Fab molecule which consists of a heavy chain of SEQ ID NO: 99, and a light chain of SEQ ID No: 101.

Nucleic acids encoding Fab constructs may be used to express such heavy and light chains in host cells, like E. coli, Pichia pastoris, or mammalian cell lines (e.g. CHO, or NSO). Processes are known in the art which allow proper folding, ation, and disulfide bonding of these chains into functional Fab molecules comprising a Fd fragment and a light chain (Burtet et al., J. Biochem. 2007, 142(6), 665-669; Ning et al., Biochem.

Mol. Biol. 2005, 38: 204-299; Quintero-Hernandez et al., Mol. lmmunol. 2007, 44: 1307- 1O 1315; s et al. J. togr. B. Analyt. l. Biomed. Life Sci. 2003;786:161- 176.).

In particular, Fab molecules of the invention can be produced in CHO cells as follows.

CHO-DG44 cells (Urlaub,G., Kas,E., Carothers,A.M., and ,L.A. (1983). Deletion of the diploid dihydrofolate reductase locus from cultured mammalian cells. Cell 33, 405- 412.) growing in suspension in serum-free medium are transfected with expression constructs encoding heavy and light chain of the Fab molecule using LipofectamineTM and PlusTM reagent rogen) according to the manufacturer’s instructions. After 48 hours, the cells are subjected to selection in medium containing 200ug/mL of the antibiotic G418 and without hypoxanthine and ine to generate stably transfected cell populations.

These stable transfectants are subsequently ted to gene amplification by adding methotrexate (MTX) in increasing concentrations (up to 100 or 400 nM) into the culture medium. Once the cells have adapted, they are subjected to fed-batch fermentations over to 11 days to produce Fab protein material.

Suspension cultures of CHO-DG44 cells and stable transfectants thereof are incubated in chemically defined, serum-free cultivation media. Seed stock cultures are sub-cultivated every 2—3 days with g densities of 3 X105—2 x 105 cells/mL respectively. Cells are grown in shake flasks in Multitron HT tors (lnfors) at 5% C02, 37°C and .

For fed-batch experiments, cells are seeded at 3x105 cells/mL into shake flasks in Bl- proprietary tion medium without antibiotics or MTX. The cultures are agitated at 120 rpm in 37°C and 5% C02 which is later reduced to 2% as cell numbers increase.

Culture parameters including cell count, viability, pH, glucose and lactate concentrations are determined daily and pH is adjusted to pH 7.0 using carbonate as needed. BI- etary feed solution is added every 24 hrs. Samples from the supernatant are taken at different time points to dermine the Fab product concentration by ELISA. After 10 to 11 days, the cell culture fluid is harvested by fugation and transferred to the purification labs.

The Fab molecule is purified from the supernatant of the fed-batch cultures by means of tography and filtration. As primary capture step affinity chromatography, e.g.

Protein G or Protein L, are applied. Alternatively, in case of low binding affinities and ties, the Fab is captured by cation exchange chromatography (CEX) exploiting the pl of the molecule. Host cell ns and contaminants, e.g. DNA or viruses, are removed by additional orthogonal purification steps.

Identity and product quality of the produced Fab molecule are analysed by electrophoretic methods, e.g. SDS-PAGE, by which Fab can be detected as one major band of approx. 50 kDa. Further assays for terization of the Fab product include mass spectrometry, isoelectric ng and size ion chromatography. Binding activity is followed by BlAcore analysis.

Quantification of Fab or full-length lgG molecules in the supernatant of the cell cultures is performed via ch enzyme linked immunosorbent assay (ELISA). The full-length lgG can be detected using antibodies raised against Fc fragment (Jackson lmmuno Research Laboratories) and human kappa light chain (peroxidase-conjugated, Sigma). The Fab fragment is immobilized by goat polyclonal anti-Human lgG (H and L, Novus) and detected by sheep polyclonal antibodies raised against human lgG (peroxidase-conjugated, The Binding Site).

Fab molecules can also be generated from full-length antibody molecules by enzymatic ge. The advantage of this approach is that platform processes for robust and efficient fermentation and purification are applicable which are le for up-scaling and high yields at the desired product quality. For purification affinity tography using a recombinant Protein A resin can be used as primary capture step which usually results in high purities.

For this purpose, the heavy chain ng Fab ces are fused to the Fc-region of a human lgG antibody molecule. The resulting expression constructs are then transfected into CHO-DG44 cells growing in suspension in serum-free medium using lipofection. After 48 hours, the cells are subjected to selection in medium containing 200ug/mL of the antibiotic G418 and without hypoxanthine and thymidine to generate stably transfected cell populations. These stable transfectants are subsequently subjected to gene amplification by adding methotrexate (MTX) in increasing concentrations (up to 100 or 400 nM) into the e medium. Once the cells have adapted, they are subjected to fed- batch fermentations over 10 to 11 days to produce lgG protein material.

The lgG n is purified from the culture atant by using recombinant Protein A- affinity chromatography. To obtain the desired neutralizing Fab fragment the full-length lgG is then incubated in the presence of papain which cleaves the lgG within the hinge region, thereby releasing two Fab fragments and the Fc-moiety.

The Fab molecule is isolated by affinity chromatography, e.g. Protein G or Protein L.

Alternatively, in case of low binding ties and capacities, the Fab is captured by cation exchange chromatography (CEX) exploiting the pl of the molecule. Host cell proteins and contaminants, e.g. Papain, DNA or viruses, are removed by additional onal cation steps.

In another aspect of the ion, the antibody molecule is an amino acid sequence t of an antibody molecule as described herein.

Amino acid sequence variants of antibodies can be prepared by introducing appropriate nucleotide changes into the antibody DNA, or by peptide synthesis. Such variants include, for example, deletions from, and/or insertions into and/or substitutions of, residues within the amino acid sequences of the antibodies of the examples herein. Any combination of deletions, insertions, and substitutions is made to arrive at the final construct, ed that the final construct possesses the desired characteristics. The amino acid changes also may alter post-translational ses of the humanized or variant antibody, such as changing the number or position of glycosylation sites.

A useful method for identification of certain es or regions of the antibody that are preferred locations for mutagenesis is called "alanine scanning mutagenesis," as described by Cunningham and Wells (Science, 244:1081-1085 (1989)). Here, a residue or group of target residues are identified (e.g., charged residues such as arg, asp, his, lys, and glu) and replaced by a neutral or vely charged amino acid (typically alanine) to affect the interaction of the amino acids with antigen. Those amino acid locations demonstrating functional sensitivity to the substitutions then are refined by introducing further or other variants at, or for, the sites of substitution. Thus, while the site for introducing an amino acid sequence variation is predetermined, the nature of the mutation per se need not be predetermined. For example, to analyze the performance of a mutation at a given site, alanine scanning or random mutagenesis is ted at the target codon 1O or region and the expressed antibody variants are ed for the desired activity.

Amino acid sequence insertions include amino- and/or yl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as equence insertions of single or multiple amino acid residues. Examples of al insertions include an antibody fused to an epitope tag. Other insertional variants of the dy molecule include a fusion to the N- or C-terminus of the dy of an enzyme or a polypeptide which increases the serum half-life of the antibody.

Another type of t is an amino acid substitution variant. These variants have at least one amino acid residue in the antibody molecule removed and a different residue inserted in its place. The sites of greatest interest for substitutional mutagenesis include the hypervariable regions, but FR alterations are also contemplated. Conservative substitutions are shown in the Table below under the heading of "preferred substitutions".

If such substitutions result in a change in biological activity, then more substantial changes, denominated "exemplary substitutions", or as further bed below in reference to amino acid s, may be introduced and the products screened.

Original e Exemplary Substitutions Preferred Substitutions Ala (A) val; leu; ile val Arg (R) lys; gln; asn lys Asn (N) gln; his; asp, lys; arg gln Asp (D) glu; asn glu Cys (C) ser; ala ser Gln (Q) asn; glu asn Glu (E) asp; gln asp Gly (G) ala ala His (H) arg; asn; gln; lys; arg lie (I) leu; val; met; ala; phe; norleucine leu Leu (L) ile; norleucine; val; met; ala; phe ile Lys (K) arg; gln; asn arg Met (M) leu; phe; ile leu Phe (F) tyr; leu; val; ile; ala; tyr Pro (P) ala ala Ser (8) thr thr Thr (T) ser ser 1O Trp (W) tyr; phe tyr Tyr (Y) phe;trp; thr; ser phe Val (V) leu; ile; met; phe ala; norleucine; leu In protein chemistry, it is generally ed that the biological properties of the antibody can be accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hobicity of the molecule at the target site, or (c) the bulk of the side chain. Naturally occurring residues are divided into groups based on common side-chain ties: (1) hydrophobic: norleucine, met, ala, val, leu, ile; (2) neutral hydrophilic: cys, ser, thr; (3) acidic: asp, glu; (4) basic: asn, gin, his, lys, arg; (5) residues that influence chain orientation: gly, pro; and (6) aromatic: trp, tyr, phe.

Non-conservative tutions will entail ging a member of one of these classes for another class.

Any cysteine residue not involved in maintaining the proper conformation of the humanized or variant antibody also may be substituted, generally with serine, to improve the oxidative stability of the le, prevent aberrant crosslinking, or provide for established points of conjugation to a cytotoxic or cytostatic compound. sely, cysteine bond(s) may be added to the antibody to e its stability (particularly where the antibody is an antibody fragment such as an Fv fragment).

A type of substitutional variant involves substituting one or more hypervariable region residues of a parent antibody (e.g., a humanized or human antibody). Generally, the resulting variant(s) ed for further development will have improved biological properties relative to the parent antibody from which they are generated. A convenient way for generating such substitutional variants is affinity maturation using phage display. y, several hypervariable region sites (e.g., 6-7 sites) are mutated to generate all possible amino substitutions at each site. The antibody variants thus generated are displayed in a monovalent fashion from filamentous phage les as fusions to the gene lll product of M13 packaged within each particle. The phage-displayed variants are then 1O screened for their biological activity (e.g., binding affinity). In order to identify candidate hypervariable region sites for modification, alanine scanning mutagenesis can be performed to identify hypervariable region residues contributing significantly to antigen binding. Alternatively, or in addition, it may be cial to e a l structure of the antigen-antibody complex to identify t points n the antibody and human Dabigatran. Such contact residues and neighboring residues are candidates for substitution according to the ques elaborated herein. Once such variants are generated, the panel of variants is subjected to screening as described herein and antibodies with superior properties in one or more relevant assays may be selected for further development.

Another type of amino acid variant of the antibody alters the original ylation pattern of the antibody. By "altering" is meant deleting one or more carbohydrate moieties found in the antibody, and/or adding one or more glycosylation sites that are not present in the antibody.

In some embodiments, it may be desirable to modify the antibodies of the invention to add glycosylations sites. Glycosylation of antibodies is typically either ed or O-linked. N- linked refers to the attachment of the carbohydrate moiety to the side chain of an asparagine residue. The tripeptide sequences asparagine-X—serine and asparagine-X- threonine, where X is any amino acid except proline, are the recognition sequences for enzymatic attachment of the carbohydrate moiety to the asparagine side chain. Thus, the ce of either of these tripeptide ces in a polypeptide creates a potential glycosylation site. O-linked glycosylation refers to the attachment of one of the sugars N- alactosamine, galactose, or xylose to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or oxylysine may also be used. Thus, in order to glycosylate a given protein, e.g., an antibody, the amino acid sequence of the protein is engineered to contain one or more of the above-described tripeptide sequences (for N-linked glycosylation sites). The alteration may also be made by the addition of, or substitution by, one or more serine or ine residues to the sequence of the original antibody (for O-linked glycosylation sites).

Nucleic acid molecules encoding amino acid sequence ts of the antibody are prepared by a variety of methods known in the art. These methods include, but are not limited to, isolation from a natural source (in the case of naturally occurring amino acid sequence variants) or preparation by oligonucleotide-mediated (or irected) mutagenesis, PCR mutagenesis, and cassette mutagenesis of an earlier prepared t or a riant version of an antibody molecule as described herein. As outlined above, the antigen of the dy molecule of the invention is an anticoagulant. The antigen is used to generate the antibody molecule, either by immunization of an animal, or by selecting antibody sequences from sequence libraries, as with phage display methods.

Immunization protocols for animals are well-known in the art. To achieve a proper immune se, it may be necessary to combine the antigen with an adjuvant, like aluminium phosphate, aluminium hydroxide, squalene, or Freund’s complete/incomplete adjuvant.

The antigens in the context of the present invention, like dabigatran, are mostly ably small c molecules, which sometimes do not stimulate antibody formation upon administration to an animal. It may ore be necessary to attach the antigen to a macromolecule, as a hapten.

In a further aspect, the present invention relates to an antibody molecule as described above for use in medicine.

In a further , the present invention relates to a pharmaceutical composition comprising an antibody molecule as described before, and a pharmaceutical carrier.

To be used in therapy, the antibody molecule is included into pharmaceutical itions appropriate to facilitate administration to s or humans. Typical formulations of the antibody molecule can be prepared by mixing the dy molecule WO 30834 with physiologically acceptable carriers, excipients or stabilizers, in the form of lyophilized or otherwise dried formulations or aqueous solutions or s or non-aqueous suspensions. Carriers, excipients, modifiers or stabilizers are nontoxic at the dosages and concentrations employed. They include buffer systems such as phosphate, citrate, acetate and other anorganic or c acids and their salts; antioxidants including ascorbic acid and methionine; preservatives such as octadecyldimethylbenzyl ammonium chloride; hexamethonium de; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); proteins, such as serum albumin, gelatin, or 1O immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone or polyethylene glycol (PEG); amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, harides, oligosaccharides or polysaccharides and other carbohydrates ing glucose, mannose, sucrose, trehalose, dextrins or dextrans; chelating agents such as EDTA; sugar alcohols such as, mannitol or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g., Zn-protein xes); and/or ionic or non-ionic surfactants such as TWEENTM (polysorbates), PLURONICST'V' or fatty acid , fatty acid ethers or sugar esters. Also organic solvents can be contained in the antibody formulation such as l or isopropanol. The excipients may also have a e-modifying or absorption-modifying function.

In one aspect, the ceutical compositon comprises the antibody molecule in an aqueous, buffered solution at a concentration of 10-20 mg/ml, or a lyophilisate made from such a solution.

The preferred mode of application is parenteral, by on or injection (intraveneous, intramuscular, subcutaneous, intraperitoneal, intradermal), but other modes of application such as by inhalation, ermal, intranasal, buccal, oral, may also be applicable.

In a further aspect, the present invention relates to an dy molecule as described above for use in the therapy or prevention of side effects of anticoagulant therapy, in ular bleeding events.

In a further aspect, the present invention relates to the use of an antibody molecule as described herein for the manufacture of a medicament for the treatment or prevention of a WO 30834 disease or disorder as described herein, in ular the side effects of anticoagulant therapy.

In a further aspect, the present invention relates to an antibody molecule as described above for use in the reversal of an overdosing of an agulant, in ular dabigatran or dabigatran ate.

In a further aspect, the present invention s to an antibody molecule as described above for use as an antidote of an anticoagulant, in particular dabigatran or dabigatran 1O exetilate.

In a further aspect, the present invention relates to a method of treatment or prevention of side effects of anticoagulant therapy, comprising administering an ive amount of an antibody molecule as described above to a patient in need f.

In a further aspect, the present invention relates to a method of treatment of an overdosing event in agulant therapy, comprising administering an effective amount of an antibody molecule as described above to a patient in need thereof.

In a further aspect, the present invention relates to a method for reducing the concentration of dabigatran or 1-O-acylglucuronide of dabigatran in plasma of a patient being treated with dabigatran, dabigatran etexilate, a prodrug of dabigatran or a pharmaceutically acceptable salt f, comprising the step of administering a reversal agent that neutralizes the activity of dabigatran or 1-O-acylglucuronide in the patient.

In a further aspect, the present invention s to a reversal agent that neutralizes the activity of dabigatran or 1-O-acylglucuronide for use in a patient being d with dabigatran, dabigatran etexilate, a prodrug of dabigatran or a pharmaceutically acceptable salt thereof, wherein the patient either has major bleeding considered life-threatening or leading to hemodynamic compromise, or wherein the patient requires emergency medical procedures.

In a further aspect, the present invention s to a method for reducing the concentration of dabigatran or 1-O-acylglucuronide of dabigatran in plasma of a patient being treated with dabigatran, dabigatran etexilate, a prodrug of dabigatran or a pharmaceutically acceptable salt thereof, wherein the patient either has major bleeding considered life-threatening or leading to hemodynamic compromise, or wherein the patient requires emergency medical procedures, comprising the step of administering a reversal agent that neutralizes the activity of tran or 1-O-acylglucuronide in the patient.

In a r aspect, the present invention s to a method of reversal of the anticoagulant effect of dabigatran or 1-O-acylglucuronide of tran in a patient being 1O treated with tran, dabigatran etexilate, a prodrug of dabigatran or a pharmaceutically acceptable salt thereof, wherein the patient either has major bleeding considered life-threatening or leading to hemodynamic compromise, or wherein the patient requires emergency medical procedures, comprising the step of administering a reversal agent that neutralizes the activity of dabigatran or ylglucuronide in the patient.

In a preferred ment, the reversal agent is an antibody molecule against dabigatran which is capable of lizing the anticoagulant ty of dabigatran, dabigatran etexilate, and/or 1-O-acylglucuronide. In another preferred ment, the reversal agent is an antibody molecule against dabigatran as bed herein.

Preferably, the concentration of dabigatran or 1-O-acylglucuronide of dabigatran in plasma is greater than 0 nM but less than 1000 uM and wherein the reversal agent used to neutralize the activity of dabigatran or 1-O-acylglucuronide is present in a stoichiometric amount of dabigatran or 1-O-acylglucuronide of dabigatran to reversal agent.

In a further , the concentration of dabigatran or 1-O-acylglucuronide of dabigatran in plasma is greater than 0 nM but less than 1000 uM, and wherein the reversal agent used to neutralize the activity of dabigatran or 1-O-acylglucuronide is present in a molar ratio of between 1:1 and 1:100 of dabigatran or 1-O-acylglucuronide of dabigatran to reversal agent.

In a further , the concentration of dabigatran or 1-O-acylglucuronide of dabigatran in plasma is n 30 nM and 1000 uM, and wherein the reversal agent used to neutralize the activity of dabigatran or 1-O-acylglucuronide is present in a ratio of between nM and 1000 uM of dabigatran or 1-O-acylglucuronide of dabigatran to reversal agent.

In another aspect, the present invention s to a method for reversing or reducing the activity of dabigatran or 1-O-acylglucuronide of dabigatran in a t experiencing bleeding or at risk for bleeding due to an impaired clotting ability or trauma, sing the steps of: (a) determining the amount of dabigatran or 1-O-acylglucuronide of dabigatran present in the patient; 1O (b) administering an effective amount of an agent to reverse or reduce the activity of dabigatran or 1-O-acylglucuronide of dabigatran determined in the patient; and (c) monitoring a thrombin clotting time of the patient to ensure a reversal or ion in activity of dabigatran or ylglucuronide of tran has been reached.

In a preferred aspect, the reversal of activity of dabigatran or 1-O-acylglucuronide of dabigatran is 100%. In a further preferred aspect, the reduction of activity of dabigatran or 1-O-acylglucuronide of dabigatran is between 10 and 99 % of tran or 1 acylglucuronide of dabigatran in the patient.

The "therapeutically effective amount" of the dy to be administered is the minimum amount necessary to prevent, ameliorate, or treat the side effects of anticoagulant therapy, in particular the minimum amount which is effective to stop bleeding. This can be achieved with stoichiometric amounts of antibody molecule.

Dabigatran, for example, may achieve a plasma tration in the magnitude of 200 nM when given at the recommended dose. When a monovalent antibody molecule with a molecular weight of ca. 50 kD is used, neutralization may be achieved for example at a dose of about 1 mg/kg, when given intravenously as a bolus. In another embodiment, the dose of a Fab molecule applied to a human patient may be 50-1000 mg per application, for example 100, 200, 500, 750, or 1000 mg. Depending on the situation, e.g. when tran has been overdosed in a patient, it may be adequate to apply an even higher dose, e.g. 1250, 1500, 1750 or 2000 mg per application. The appropriate dose may be different, depending on the type and dose of anticoagulant stered; the time elapsed since such administration, the nature of the antigen molecule, the condition of the patient, 2012/055397 and other factors. The skilled expert knows methods to establish doses which are both eutically effective and safe.

In a further aspect, the present invention relates to an antibody molecule with binding affinity to dabigatran and/or dabigatran etexilate. Preferably, the dy molecule binds to the dabigatran and/or tran etexilate with an affinity, as determined e.g. by surface plasmon resonance analysis (Malmqvist M., ce plasmon nce for detection and measurement of antibody-antigen affinity and cs. "Curr Opin lmmunol. 1993 Apr;5(2):282—6.) or c exclusion assay (KinExA) technology (Darling, R.J., and 1O Brault P-A., “Kinetic exclusion assay technology: Characterization of Molecular Interactions.” ASSAY and Drug Development Technologies. 2004, Dec 2(6): 647-657), with a KD value ranging from 0.1 pM to 100 uM, preferably 1 pM to 100 uM, more preferably 1 pM to 1 uM.

The antibody molecules of the invention can also be used for analytical and diagnostic procedures, for example to determine antigen concentration in samples such as plasma, serum, or other body fluids. For example, the antigen molecules may be used in an enzyme-linked adsorbent assay (ELISA), like those described in the examples.

Thus, in a further aspect, the present invention relates to analytical and diagnostic kits sing antibody molecules a bed , and to respective analytical and diagnostic methods.

In a r aspect, the present invention relates to a method of manufacturing an antibody molecule of any one of the preceding claims, comprising (a) ing a host cell comprising one or more nucleic acids encoding said antibody molecule in functional association with an expression control sequence, (b) cultivating said host cell, and (c) recovering the antibody molecule from the cell culture.

The invention further provides an article of manufacture and kit containing materials useful for neutralization of oral anticoagulants, particularly direct thrombin inhibitors. The article of manufacture comprises a container with a label. Suitable containers include, for 2012/055397 example, bottles, vials, and test tubes. The containers may be formed from a variety of materials such as glass, metal, plastic or combinations f. The ner holds a pharmaceutical composition comprising the antibody described herein or dabigatran, dabigatran etexilate, a prodrug of dabigatran or a pharmaceutically acceptable salt thereof. The active agent in the pharmaceutical composition is the particular antibody or dabigatran, dabigatran ate, a prodrug of dabigatran or a pharmaceutically acceptable salt thereof. The label on the container of the antibody indicates that the ceutical composition is used for lizing or lly neutralizing dabigatran, dabigatran etexilate, a prodrug of dabigatran or a ceutically acceptable salt thereof in vivo.

The kit of the invention comprises one or more of the containers described above. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use.

In one embodiment of the invention, the kit comprises an antibody of any one the antibodies described herein or a pharmaceutical composition thereof. For example, the kit may comprise (1) any one the antibodies described herein or a pharmaceutical composition thereof, (2) a container and (3) a label.

In r ment, the kit comprises an antibody of any one the antibodies described herein or a pharmaceutical composition thereof, and dabigatran, dabigatran etexilate, a prodrug of dabigatran or a pharmaceutically acceptable salt thereof. The form of dabigatran, dabigatran etexilate, a prodrug of dabigatran or a pharmaceutically acceptable salt thereof may be in the form of a solid, liquid or gel. In a preferred embodiment, the pharmaceutically acceptable salt of dabigatran etexilate is a mesylate salt. In yet another preferred embodiment, the strength per doage unit of the tran, tran etexilate, prodrug of dabigatran or pharmaceutically able salt thereof is between about 50 mg and about 400 mg, about 75 mg and about 300 mg, about 75 mg and 150 mg, or about 110 mg and about 150 mg, given once-a-day (QD) or a-day (BID). For example, the kit may comprise (1) any one the antibodies described herein or a pharmaceutical composition thereof, (2) a pharmaceutical composition of dabigatran, dabigatran etexilate, a prodrug of dabigatran or a pharmaceutically acceptable salt thereof, (3) a container and (4) a label.

In an alternate embodiment, the kit comprises (1) a first pharmaceutical composition comprising dabigatran, tran etexilate, a prodrug of dabigatran or a pharmaceutically acceptable salt thereof, (2) a second pharmaceutical composition comprising any one the antibodies described herein or combination thereof, (3) instructions for separate admininstration of said first and second pharmaceutical compositions to a patient, wherein said first and second pharmaceutical compositions are contained in separate containers and said second pharmaceutical composition is administered to a patient requiring neutralization or partial neutralization of dabigatran or 1-O-acylglucuronide of dabigatran.

The invention also provides a diagnostic method to neutralize or partially neutralize dabigatran or 1-O-acylglucuronide of dabigatran in a t being d with dabigatran, dabigatran etexilate, a prodrug of dabigatran or a pharmaceutically acceptable salt thereof, sing administering any one of the antibodies described herein, a ation thereof or a pharmaceutical composition thereof. Specifically, the ion provides a method for neutralizing or partially neutralizing dabigatran or 1 acylglucuronide of dabigatran in a patient comprising the steps of (a) ming that a patient was being d with dabigatran, dabigatran etexilate, a prodrug of dabigatran or a pharmaceutically acceptable salt thereof, and the amount that was taken by the patient; (b) neutralizing dabigatran or 1-O-acylglucuronide with any one of the antibodies described herein or ation thereof prior to performing a clotting or coagulation test or assay wherein dabigatran or the 1-O-acylglucuronide of dabigatran would interfere with the accurate read out of the test or assay results; (c) performing the clotting or coagulation test or assay on a sample taken from the patient to determine the level of clot formation without dabigatran or 1-O-acylglucuronide of tran present; and (d) adjusting an amount of dabigatran, dabigatran etexilate, a prodrug of dabigatran or a pharmaceutically acceptable salt thereof administered to the patient in order to achieve the appropriate balance between clot formation and degradation in a patient. The molar ratio of antibody to tran or ylglucuronide of dabigatran is in the molar ratio of between 0.1 and 100, preferably between 0.1 and 10. The accurate read out of the test or assay result may be an accurate read out of ogen levels, activated protein C resistance or related tests.

EXAMPLES I. PRODUCTION OF POLYCLONAL ABIGATRAN ANTIBODIES For the tion of polyclonal anti-dabigatran antibodies, 3 different immunogens were produced with two different haptens and different molar input ratios of the hapten and the carrier protein (BSA).

For the screening, an enzyme horseradish peroxidase (HRP)-conjugate was produced and an enzyme-immunosorbent assay (ELISA) developed. 1O Further purification of the polyclonal antibodies was performed by affinity chromatography on protein A sepharose FF. 1. MATERIALS AND S Test nd (dabigatran) a—obigatran, zwitter ion Structural formula: 25H25N703 olecular weight: 471.5 g/mol 1.1 HAPTEN USED FOR SYNTHESIS OF IMMUNOGEN AND TRACER Haptem Structural formula ongand: HZN/\/\/H\n/\/N\©o C30H35N802 * HCI molecular weight: 577.13 g/mol Hapten2 Structural formula ongand: /\/N N O N / X HCI C27H31N902 * HCI molecular : 550.07 g/mol 1.2 SYNTHESIS OF S The haptens Hapten1 and Hapten2 were synthesized as follows: Hagten‘l 2-[(4-Carbamimidoyl-phenylamino)-methyl]methyl-1H-benzoimidazole carboxylic acid [2-(4-amino-butylcarbamoyl)-ethyl]-phenyl-amide >—\ NH N—<: :>—< /\/\/ 2 H2N W 1a 3-[(4-Methylaminonitro-benzoyl)-phenyl-amino]-propionic acid methyl ester O +-_O ,o N o’ H3C W To a solution of 4-methylaminonitro-benzoic acid chloride (23.3 mmol) and 3-phenyl- amino-propionic acid methyl ester (23.3 mmol) in 80 mL dry tetrahydrofuran (THF) triethylamine (50.2 mmol) was added dropwise under stirring at room temperature. After 1O three hours the rection mixture was evaporated to dryness, the remaining solid triturated with water and the solid product isolated through tion.

Yield: 99% C18H19N305 (357.36) TLC a gel; Dichloromethane/ethanol 19:1): Rf: 0.48 lb 3-[(3-Aminomethylamino-benzoyl)-phenyl-amino]-propionic acid methyl ester ,0 N H30 \H/V The nitro group of product 1a was d by hydrogenation at room temperature in ethanol with Pd (10% on charcoal) as catalyst.

Yield: 99% C18H21N303 (327.38) TLC (silica gel; Dichloromethane/ethanol 9:1): Rf: 0.23 Mass spectrum (ESI): [M+H]+ = 328 1O 1c [2-(4-Cyano-phenylamino)-acetylamino]methylamino-benzoyl}-phenyl- amino)-propionic acid methyl ester H C/OWN 3 \ The t of lb (23.2 mmol) and N-(4-cyano-phenyl)-glycine (23.2 mmol) were coupled with CDI (23.2 mmol) in dry THF at room temperature. After completion of the reaction the mixture was evaporated to dryness and the crude product was used without further purification.

Yield: 97% C27H27N5O4 (485.54) Mass spectrum (ESI): [M+H]+ = 486 ﬂ 3-({2-[(4-Cyano-phenylamino)-methyl]—1-methyl-1H-benzoimidazolecarbonyl}- phenyl-amino)-propionic acid methyl ester A on of the product of 1c (22.6 mmol) in 100 mL concentrated acetic acid was heated to reflux for one hour. The solution was then evaporated to dryness, the ing solid triturated with water and under stirring the pH was adjusted to about 8-9. The crude product was isolated through extraction with ethyl acetate and purified by chromatography 1O on silica gel (eluent: dichloromethane/ethanol 1:1).

Yield: 58% C27H25N503 (467.52) TLC (silica gel; Dichloromethane/ethanol 9:1): Rf: 0.71 Mass spectrum (ESI): [M+H]+ = 468 1_e 3-({2-[(4-Cyano-phenylamino)-methyl]—1-methyl-1H-benzoimidazolecarbonyl}- phenyl-amino)-propionic acid To a on of the product of 1d (13.0 mmol) in 100mL methanol sodium hydroxide (20.0 mmol) was added. The mixture was d for 2.5 hours at 40°C and then evaporated to dryness. The remaining solid was stirred with 100 mL water and the pH was adjusted to about 6 with concentrated acetic acid. The precipitated product was isolated by filtration, washed with water and dried at 60°C.

Yield: 88% C26H23N503 9) TLC (silica gel; Dichloromethane/ethanol 9:1): Rf: 0.33 Mass spectrum (ESI): [M+H]+ = 454 1f {4-[3-({2-[(4-Cyano-phenylamino)-methyl]—1-methyl-1H-benzoimidazole carbonyl}-phenyl-amino)-propionylamino]-butyl}-carbamic acid tert-butyl ester /> \ N N %%12;:TN i430 0 \© A solution of the product of 1e (5.23 mmol), 2-(1H-benzotriazoleyl)-1,1,3,3- tetramethyluronium tetrafluoroborate (TBTU, 5.23 mmol) and N-methyl-morpholin (5.23 mmol) in 20 mL DMF was stirred at room temperature for 30 s. Then (4-aminobutyl )-carbamic acid tert-butyl ester (5.23 mmol) was added and the mixture stirred at room temperature for another 24 hours. The mixture was then diluted with water (100 mL) and the product was isolated through extraction with ethyl acetate.

Yield: 92% C35H41N7O4 5) TLC (silica gel; romethane/ethanol 9:1): Rf: 0.51 lg 2-[(4-Carbamimidoyl-phenylamino)-methyl]methyl-1H-benzoimidazole carboxylic acid [2-(4-amino-butylcarbamoyl)-ethyl]—phenyl-amide H NH o N/ N H < > < H NH HZN/\/\/ WN 2 The product of 1f (4.81 mmol) was dissolved in a ted solution of HCI in ethanol (250 mL), the mixture stirred at room temperature over night and then evaporated to dryness at °C. The remainig raw material was dissolved in 200 mL dry ethanol, then ammonium carbonate (48.1 mmol) was added and the mixture stirred at room temperature over night.

After ation of the solvent the remaining raw material was triturated with ca. 5 mL ethanol, the undissolved material separated by filtration and the solvent evaporated at °C. The product was then dissolved in 30 mL water, the solution stirred with ca.2g 1O charcoal, filtered and evaporated to dryness.

Yield: 90% CsoHssNBOZ (540.67) TLC (reversed phase RP-8; ol/5% aqueous NaCl solution 9:1): R = 0.79 Mass spectrum (ESI): [M+H]+ = 541 ‘ = 575/7 Hapten2 2-[(4-Carbamimidoyl-phenylamino)-methyl]methyl-1H-benzoimidazole carboxylic acid [2-(2-amino-ethylcarbamoyl)-ethyl]-pyridinyl-amide H H HZN/\/ WN N 2 O N / 2a [(4-Cyano-phenylamino)-methyl]—1-methyl-1H-benzoimidazolecarbonyl}- pyridinyl-amino)-propionic acid CH3 3 / / O\ N N4©7:NH o H3CVOWN \ \ ‘ HOWN ‘ o N / o N / To a on of sodium hydroxide (50.0 mmol) in 500 mL ethanol and 50 mL water was added 3-({2-[(4-Cyano-phenylamino)-methyl]methyl-1H-benzoimidazolecarbonyl}- pyridinyl-amino)-propionic acid ethyl ester (41.4 mmol). The mixture was stirred at room temperature for three hours, then ca. 350 mL ethanol were distilled off, ca. 100 mL water was added and the pH was adjusted to 6. Then diethylether (50 mL) was added and the mixture stirred over night. The product was isolated by filtration and used without further purification. 1O Yield: 78% N603 (454.48) 2b {2-[3-({2-[(4-Cyano-phenylamino)-methyl]methyl-1H-benzoimidazole carbonyl}-pyridinyl-amino)-propionylamino]-ethyl}-carbamic acid tert-butyl ester /> \ O N :N H N 3C 0 U A solution of the product of 2a (2.20 mmol), 2-(1H-benzotriazoleyl)—1,1,3,3- tetramethyluronium luoroborate (TBTU, 2.20 mmol) and N-methyl-morpholin (2.20 mmol) in dry tetrahydrofuran (100 mL) was stirred at room temperature for 15 minutes.

Then (2-amino-ethyl)-carbamic acid tert-butyl ester (2.20 mmol) was added and the mixture stirred at room temperature for another 24 hours. The mixture was then diluted with 40 mL water, the product was ed through extraction with ethyl acetate and purified by chromatography (silica gel; dichloromethane/methanol 15:1).

Yield: 61% N804 (596.68) Mass spectrum (ESI): [M+H]+ = 597 [M+H]' = 595 2c 2—[(4-Carbamimidoyl-phenylamino)-methyl]methyl-1H-benzoimidazole carboxylic acid [2-(2-amino-ethylcarbamoyl)-ethyl]-pyridinyl-amide H H4?H NH HZN/\/ WN N 2 O N / The product of 2b (1.34 mmol) was added to a saturated HCI solution in dry ethanol (30 1O mL). The solution was stirred at room temperature for 5 hours, then evaporated to dryness at 30°C. Ethanol (30 mL) and ammonium carbonate (13.0 mmol) were added and the mixture stirred at room temperature over night. The solvent was then evaporated, the residual material was triturated 5 times with ca. 4 mL of a mixture of dichloromethane/methanol (30:1), ed and ated in order to separate the product from nic salts.

Yield: 27% C27H31N902 (513.61) Mass spectrum (ESI): [M+Cl]' = 548/50 [M+HC|+C|]' = 584/6 [M+H]+ = 514 2. ALS 2.1 CHEMICALS FOR REAGENT SYNTHESIS name specification upplier atalogue no. 1,4-Benzoquinone Bovines Serum Albumin (BSA) 1,1’-CarbonyI-di-(1,2,4- Freund’s adjuvant (CFA) Freund’s adjuvant (IFA) Glycerine Sodium perborate 2012/055397 2.2 CHEMICALS FOR ELISA analytical grade Riedel-DeHaenf-3114 analytical grade Riedel-De Haen £0743 2. 3 S FOR ELISA . .05 M NazI'IPO4 / KH2PO4 0.15 M NaCl, pH = 7.4 A weeks at approximately +4°C buffer 2 s buffer 1, with 5 g/l BSA ssay buffer stability. 10 days at approximately +4°C s buffer 1, ith 5 g/l BSA and 0.1 g/L thimerosal A weeks at approximately +4°C -phenylene diamine .5 mmol/L sodium perborate itric acid: . months at approximately +4°C ith perborate: days at approximately +4°C ash solution ater, 0.5 g/L Tween 20 late washing stability: 10 days at ambient temperature ' .25 M H2804 rrests o-phenylene oiamine colour years at ambient temperature oevelopment Water from an at Maxima-HPLC ultra pure water processing system was used to prepare buffer solutions. 3. SYNTHESIS OF IMMUNOGENS In order to stimulate the immune system of rabbits to produce onal antibodies against dabigatran, three immunogens (lot. nos. GL256, GL258, and GL262,) were synthesized by coupling the haptens HAPTEN1 and HAPTEN2 to the carrier n bovine serum albumin (BSA) using 1,4-benzoquinone or 1,1’-carbonyl-di-(1,2,4-triazol) as coupling reagent.

For the synthesis of GL256, 1,4-benzoquinone was used as a homobifunctional compound with two ve sites. First it reacts at an acidic pH with amino groups at only one of the two sites and at an alkaline pH at the other site with minimal polymerization.

GL258 and GL262 were synthesized using arbonyl-di-(1,2,4-triazol) as coupling reagent with different input ratios of the hapten to the r protein. 3.1 SYNTHESIS OF GL256 To the solution of 0.75 uMol BSA in 8.5 mL 0.1 M KHZPO4-buffer (pH = 4.5), 0.416 mMol 1,4-benzoquinone (in 1.5 mL ethanol) was added and incubated for 1.5 h in the dark at room temperature. AftenNards the solution passed a sephadex G25 column equilibrated in 0.15 M NaCl to eliminate the excess of 1,4-benzoquinone (final volume 12.5 mL). 2.5 mL (0.15 uMol) of the purified BSA-solution were added slowly under stirring to a solution of the 525 uMol hapten HAPTEN1 dissolved in 2 mL 0.1 M NaHCOs,/Na2COS- buffer 5). During addition of the BSA solution the pH was adjusted to approximately 8.0. The molar input ratio of the hapten and the carrier protein was 3500:1.

After incubation at room temperature over night the immunogen was dialysed 6 times against 1 litre of aqua. dest. Thin-layer chromatography showed that no spots of d hapten remained in the hapten-carrier conjugates.

The immunogen was stored frozen in aliquots at -20°C. The degree of substitution of BSA with hapten in the supernatant of the immunogen was about 1:18 as determined by UV absorption spectrometry at 302 nm. The content of immunogen in the final solution was 0.75 mg GL256 / mL 3.2 SYNTHESIS OF GL258 A solution of 158 uMol HAPTEN2 in 6.3 mL N,N-dimethylformamide (DMF) was ed at room temperature. 158 uMol 1,1’-carbonyl-di-(1,2,4-triazol) was added and incubated first for 4 hours at 10°C and ards for 30 min at room temperature. The chemical reaction was d with thin-layer chromatography and was about 20-25%.

Then 0.75 uMol BSA were dissolved in 2 mL 0.13 M NaHCOs and 1 mL N,N- dimethylformamide (DMF) was added dropwise under stirring. The pH was adjusted to approximately 8.3. AftenNards the hapten solution (6.3 mL) and 4 mL 0.13 M NaHCOs were added dropwise to the BSA on under stirring and the pH was adjusted to 8.4.

The molar input ratio of the hapten and the carrier protein was 210:1 for the immunogen GL258.

After incubation at room temperature over night under stirring ions, the immunogen was dialysed 6 times against 1 litre of aqua. dest. Thin-layer chromatography showed that no spots of unbound hapten remained in the hapten-carrier conjugates.

The immunogen was stored frozen in aliquots at -20°C. The degree of substitution of BSA with hapten in the supernatant of the immunogen was about 1:5 as determined by UV absorption spectrometry at 302 nm. The t of immunogen in the final solution was 0.28 mg GL258 / mL. 3.3 SYNTHESIS OF GL262 A solution of 225 uMol HAPTEN2 in 8.75 mL N,N-dimethylformamide (DMF) was ed at room ature. 225 uMol 1,1’-carbonyl-di-(1,2,4-triazol) was added and incubated for 4 hours at 10°C. The chemical reaction was checked with thin-layer chromatography and was about 20-25%.

Then 0.49 uMol BSA were dissolved in 2 mL 0.13 M NaHCOs and 1 mL N,N- dimethylformamide (DMF) was added dropwise under stirring. The pH was adjusted to approximately 8.2. AftenNards the hapten solution (8.75 mL) and 6 mL 0.13 M NaHCOs 1O were added dropwise to the BSA solution under stirring and the pH was adjusted to 8.3.

The molar input ratio of the hapten and the carrier protein was 460:1 for the immunogen GL262.

After incubation at room temperature over night under stirring conditions, the immunogen was dialysed 6 times against 1 litre of aqua. dest. Thin-layer chromatography showed that no spots of unbound hapten ed in the hapten-carrier conjugates.

The immunogen was stored frozen in aliquots at -20°C. The degree of substitution of BSA with hapten in the supernatant of the immunogen was about 1:32 as ined by UV absorption spectrometry at 302 nm. The content of immunogen in the final on was 0.71 mg GL262 / mL 4. SYNTHESIS OF CONJUGATE 4.1 SYNTHESIS OF GL261 A on of 37.4 uMol HAPTEN2 in 1.5 mL N,N-dimethylformamide (DMF) was prepared at room temperature. 37.5 uMol 1,1’-carbonyl-di-(1,2,4-triazol) was added and incubated first for 4 hours at 10°C and afterwards for 30 min at room temperature. The chemical reaction was checked with ayer chromatography and was about 20-25%.

WO 30834 Then 1.125 uMol enzyme horseradish peroxidase (HRP) were dissolved in 0.4 mL 0.13 M NaHCOs and 0.267 mL N,N- dimethylformamide (DMF) was added dropwise under stirring. The pH was adjusted to approximately 8.2. AftenNards 0.9 mL of the hapten solution (22.5 uMol) and 0.57 mL 0.13 M NaHCOs were added dropwise to the HRP solution under stirring and the pH was adjusted to 8.4. The molar input ratio of the hapten and the HRP was 20:1 for the HRP conjugate GL261.

After incubation at room temperature over night under stirring conditions, the HRP conjugate was ted from organic solvents and the excess of hapten by gel chromatography. The solution passed a sephadex G25 column brated with 0.1 M phosphate buffer pH 7.0.

The final tration of hapten-HRP conjugate (tracer, 5.64 mg/mL) was spiked with BSA yielding a concentration of about 10 mg/mL, an equal volume of glycerine to prevent freezing and a thymol crystal to prevent bacterial . The tracer solution was labelled as lot no. GL261 and stored in aliquots at -20°C.

The degree of substitution of HRP with hapten was 1:02 as determined by UV spectroscopy at 302 nm.

The specific activity of the tracer was measured in BSA-blocked microtiter plates using 0- phenylene-diamine (OPD) as substrate and native HRP as reference material. The e of diluted HRP standards or the hapten-HRP conjugate and substrate solution were ted for 30 min in the dark, stopped with sulphuric acid and absorption measured at 490 nm. The remaining activity was 94 % of the native HRP and the specific activity of the conjugate formulation in glycerine was 611 U/mL.

Summary of tracer specifications: HAPTEN2 - horseradish peroxidase 108 U/mg 611 U/ml (substrate Guajacol and H202, 25°C) at approximately -20°C 1:40000 . IMMUNIZATION AND PRODUCTION OF ANTIBODIES .1 IMMUNIZATION OF RABBITS Twelve female chinchilla rabbits, 3 months old, were immunized with an emulsion of 100 ug immunogen GL256, GL258 and GL262 in 0.5 mL 0.9 % NaCl solution and 0.5 mL of complete Freund’s adjuvant (CFA). Several r immunizations ed in the next month. For the third immunization 0.5 mL of lete Freund’s adjuvant (IFA) was used. Each immunization was performed at four subcutaneous and four intramuscular sites. 1O Group A — immunogen GL256 Rabbit 1 #50 Rabbit 2 #51 Rabbit 3 #52 Rabbit 4 #53 Group B — immunogen GL258 Rabbit 5 #54 Rabbit 6 #55 Rabbit 7 #56 Rabbit 8 #57 Group C — immunogen GL262 Rabbit 9 #46 Rabbit 10 #47 Rabbit 11 #48 Rabbit 12 #49 Immunization scheme in CFA Day 29 Second immunization with 100 ug immunogen / mL per animal in CFA Day 57 Third immunization with 100 ug immunogen / mL per animal in IFA the rabbit’s state of the healthy might change for the worse by the use of immunogens GL256 and GL258 rabbit 7 #56 was not treated Day 67 First bleeding (2 mL per animal) Day 81 Fourth immunization with 100 ug immunogen / mL per animal in CFA Day 91 Second bleeding (25 mL per animal) Day 112 Fifth immunization with 100 ug immunogen /mL per animal in Day 122 Assignment of the animal numbers was d Third final ng (Exsanguination)* *Rabbit no. 1-12 were exsanguinated completely 10 days after the fifth zation.

Exsanguination was performed via a carotid artery under anesthesia with xylazin (Rompun®, Bayer, Leverkusen, Germany) and ketamine hydrochloride (Ketavet®, Parke- Davis, Freiburg, Germany). .2 ANALYSIS OF RABBIT SERA Serum was prepared by centrifugation of the coagulated rabbit blood. A protein fraction was obtained by um sulphate precipitation and ing through a Sephadex G25 column.

The individual protein fractions from the rabbit sera were screened for anti-dabigatran titer by a standard ELISA ure.

Screening-ELISA: CUIIIIIIIIIIIIIIIiIIiim 'U Procedure protein fractions from each bleeding were adsorbed overnight at ambient emperature onto microtiter plates (100 uL/well; 1, 2 or 4 ug/mL) in buffer 1. ash microplates 4 times, 450 uL each block with 250 uL buffer 3 for at least 1 hour ash microplates 4 times, 450 uL each add to each well of microtiter plate in triplicate: 50 uL buffer 2 50 uL calibration standards in buffer 2 uL tran-horseradish peroxidase (H RP) conjugate GL 261 (tracer) (1/40000) seal microplates with adhesive foil, complete sample distribution for all microplates incubate for 4 h on a shaker at ambient temperature E ash microplates 4 times, 450 uL each F add to each well of iter plate 100 uL o-phenylene diamine HCI, 2.7 mg/mL (one 30 mg tablet in 11 mL buffer 4) incubate for 30 min in the dark at ambient temperature add to each well of iter plate 100 uL H2804 (2.25 M) shake for 5 minutes read absorbance; test-wavelength: 490 nm, reference-wavelength: 650 nm .3 DETECTION OF ABIGATRAN ANTIBODIES IN RABBIT SERA Last three columns: values are for dabigatran W0 2012/130834”1 2012/055397 biaeding 2 aoaﬁng can: _ahnl Finat ng inununogane caaﬂng cons j almi -4.4!. Q -«g .3 -.2. N After screening of the protein fractions of all rabbits from bleeding 2, it was obvious that rabbit no. 5 (#54) had the highest titre of anti-dabigatran antibodies with the preferred hapten HAPTEN2. Furthermore, it was possible to displace the tracer from the antibody binding sites with only low concentrations of analyte (dabigatran).

For the screening of the final bleeding 3, the cement of the tracer from the antibody binding site with low concentrations of analyte (dabigatran) was used as main decision criteria, e of the missing ation about the immunogen used. Therefore rabbits no. 2, 3 and 5 were used for the further purification. .4 PURIFICATION OF POLYCLONAL ANTIBODIES The anti-serum of rabbit no. 5 (#54) bleeding no. 2 and rabbits no. 2, 3 and 5 bleeding no. 3 (final bleeding) was precipitated with um sulphate. The precipitate was fuged for 30 min at 10°C at 4500 U/min, separated from the solution and re- dissolved in Tris buffer. This procedure was repeated. Further cation was performed by affinity chromatography on protein A ose FF. The column buffer was 0.01 M Tris pH = 7.5 and 0.1 M glycine pH = 3.0 was used for elution. Fractions containing the rabbit lgG were combined. Protein concentration was determined by UV spectroscopy at 280 nm.

Summary of antibody specifications: HAPTEN2-BSA (lot no. GL258) no. 5 (#54) serum (bleeding no. 2) 1.85 mg/mL t approximately -20°C HAPTEN1-BSA (GL256) or HAPTEN2-BSA (lot no. GL258) or HAPTEN2-BSA (lot no. GL262) no. 2 serum collected (final bleeding) t approximately -20°C HAPTEN1-BSA (GL256) or HAPTEN2—BSA (lot no. GL258) or HAPTEN2—BSA (lot no. GL262) no. 3 serum (final bleeding) '.96 mg/mL t approximately -20°C HAPTEN1-BSA (GL256) or HAPTEN2—BSA (lot no. GL258) or HAPTEN2—BSA (lot no. GL262) no. 5 serum (final bleeding) .72 mg/mL t approximately -20°C ll. Neutralization of dabigatran Two series of experiments were performed to show the effect of the antibodies against dabigatran agulant activity in vitro. The four polyclonal antibodies were received in 1O the laboratory and r tested in human plasma. This was tested in the functional assay, the thrombin clotting time.

Assay description: Briefly human plasma is ed by taking whole blood into 3.13% sodium citrate. This is then centrifuged to obtain platelet free plasma and transferred to a separate tube and frozen until required on the day of the assay. Plasma is thawed at 37°C on the day of the assay.

The thrombin clotting time is performed as follows. First thrombin is diluted to manufacturer’s specification (3 lU/mL in) in the buffer ed (Dade Behring Test kit) and prewarmed to 37°C. It is used within 2 hrs of being prepared. All assays were performed on a commercially available CL4 clotting machine (Behnk Electronics, Norderstadt, y). Fifty uL of plasma is pipetted into provided cuvettes with a magnetic stirrer and allowed to stir for 2 min in the well preheated to 37°C in the CL4 machine. At this point 100 uL of the thrombin solution is added and the time required for the plasma sample to clot is ed automatically by the CL4. Dabigatran is preincubated for 5 min in plasma in the provided cuvettes, before adding thrombin and starting the measurement. lf antibody is also tested (up 50 uL of stock solution), there is a further 5 minute incubation at 37°C before beginning clotting (Le. 10 min total incubation with tran, 5 min total incubation with antibody and then clotting is initiated with 1O throm bin).

Initially a dabigatran standard curve was performed by adding increasing concentrations of dabigatran to human plasma and ing the time to clotting after addition of thrombin (Figure 1). There was a concentration-dependent increase in the in clotting time with increasing concentrations of dabigatran.

For the first set of neutralization experiments, a clinically relevant concentration of 200 nM of tran was added to all plasma samples for neutralization. All 4 antibody preparations were able to shorten the time to clotting in plasma containing dabigatran (Figure 2). The extent of neutralization was related to the tration of protein in each antibody preparation. The antibody solution with the highest concentration (D) was then serially diluted and tested for the ability to neutralize 200 nM dabigatran anticoagulant ty in a separate set of experiments. It can be seen in Figure 3, there was a concentration dependent inhibition of dabigatran-induced anticoagulant activity with increasing concentrations of antibody. In addition when a ecific rabbit polyclonal antibody (blue square) was added to plasma containing dabigatran, it had no ability to neutralise the anticoagulant activity. The concentration dependency and the lack of neutralization of a non specific antibody indicate the reversal of anticoagulation by the antibody is specific for dabigatran.

However, these concentrations of dabigatran are clinically relevant, and bleeding or overdoses will probably occur with higher concentrations. Thus the ability of an antibody to inhibit the agulant activity of the t concentration of dabigatran (500 nM) in the standard curve in Figure 1 was also tested. Figure 4 illustrates that antibody D could also inhibit high concentrations of dabigatran.

III. PRODUCTION AND CHARACTERIZATION OF MONOCLONAL ANTI-DABIGATRAN ANTIBODIES 1. Production of monoclonal anti-dabigatran antibodies and Fabs 1O Mice were zed with Hapten1 (see Example 1.1) conjugated to carrier proteins such as hemocyanin and immunoglobulin and omas were ted according to standard procedures. Monoclonal antibodies purified from the culture atants bound to tran-protein conjugates and this binding could be competed with tran in solution with half-maximal inhibition at concentrations in the range of 1 to 10 nM. Fabs were generated by papain ge of the monoclonal antibodies with subsequent elimination of the Fc domain via Protein A.

The variable regions from the heavy and light chains of the mouse antibodies were cloned and sequenced using standard methods. The sequences were confirmed by protein analysis by mass spectrometry and N-terminal sequencing of the antibodies. DNA constructs encoding chimeric antibodies comprising the specific mouse variable regions and human lgG constant regions were generated and protein was expressed in HEK293 cells and purified.

In order to reduce potential immunogenicity, sequences of mouse monoclonal antibody clones 35E6 and 27A9 were humanized by standard s described above.

Humanized Fabs were produced by transient transfection in mammalian cells (e.g.

HEK293; CHO cells) and purified by affinity chromatography with benzamidine sepharose followed by size exclusion chromatography. 2. Characterization of monoclonal abigatran antibodies and Fabs The sequences of the variable domains of 9 monoclonal antibody clones DBGZZ (clone 22), 35E6, 45B9, 48E1, 49F8, 6A7F1, 2F1E5, 3B4E7, 1F6G8, 2D2E3, and 27A9 are depicted in Table 1. SEQ ID N03 67, 68, 69, 92, 93, 94, 99, 100 and 101 represent optimized and/or humanized sequences. The Fab compound VH5C/VK18 comprises HCVH5C (SEQ ID NO: 99) as heavy chain, and LCVK18 (SEQ ID NO: 100) as light chain.

The Fab compound K21 comprises HCVH5C (SEQ ID NO: 99) as heavy chain, and LCVK21 (SEQ ID NO: 101) as light chain. Thus, both VH5C/VK18 and VH5C/VK21 1O comprise a heavy chain variable domain with a CDR1 of SEQ ID NO: 67, a CDR2 of SEQ ID NO: 68, and a CDR3 of SEQ ID NO: 9, and a light chain variable domain with a CDR1 of SEQ ID NO: 64, a CDR2 of SEQ ID NO: 65, and a CDR3 of SEQ ID NO: 69. Both Fabs share a variable region of the heavy chain of SEQ ID NO: 92 (VH5C). K18 comprises a variable region of the light chain of SEQ ID NO: 93 (VK18), and VH5C/VK21 comprises a variable region of the light chain of SEQ ID NO: 94 (VK21).

In Table 1, the s “CDR” denote a complementarity determining , “VH” denotes the variable region of a heavy chain, “VK” denotes the le region of a kappa light chain, “CL” denotes the constant region of a light chain, and “CH” denotes the constant region of a heavy chain, “LC” denotes the light chain of an antibody molecule, and “HC” denotes the heavy chain of an antibody molecule. For example, “VHCDR1 DBGZZ” denotes the first CDR (CDR1) of the variable domain of the heavy chain of clone DBGZZ, and “DBGZZVH” denotes the variable region of the heavy chain of clone DBGZZ.

Table 1 VHCDR1 GFSLTSY: DBGZZ VHCDRZ V..WAGGSTNYNSALRS DBGZZ VHCDR3 AAYYSYYNYDGFAY DBGZZ —VKCDR1 VV()2012/130834 DBG22 VKCDRZ LVSKLDS DBG22 LQSTHFPHT DBG22 GYTFTWYWMH 35E6 ETNPRWGGTNYN 35E6 GTSGYDYFDY 35E6 RSSQTIVHSNGNTYLI 35E6 35E6 2 VKCDR3 FQASiFPYT 35E6 13 VHCDR1 GVSLFTYDVD 4589 4 VHCDR2 VMWSGGTTNYNSALKS 4589 DRWSPGGFAY 16 VKCDR1 QSSQSLLYTNGKTYLH 4589 4589 4589 9 YDVD 48E1 0 :WAGGSTNYNSALKS 48E1 1 DRWSPGGFAY 48E1 22 {SSQSLLYTNGKTYLI 48E1 23 VKCDRZ LVSKLDS 48E1 24 LQTTHFPHT 48E1 GFSLSTYGVD 49F8 26 LIWAGGSTTYNSAFKS 49F8 27 PFGY 49F8 28 {SSQSLLYTNGKTYLN 49F8 29 S 49F8 LQNSHFPHT 49F8 31 GFTFSTYGMS 6A7F1 32 SVTRGGNTYYP: 6A7F1 33 DYSGWYFDV 6A7F1 34 VKCDR1 6A7F1 VKCDR2 {VSNRFS 6A7F1 36 FQGSQIPYT 9 SAGTDYF: 40 RASESVDSYGNS FMH 4 LASWLES 42 EDPWT 43 VHCDR1 GYTFTYYT: 3B4E7 44 VHCDRZ YINPASSYTNY: 3B4E7 :--GANWDYFDY3B4E7 RSSQW QSNGNTYLH 3B4E7 3B4E7 3B4E7 1FSG8 YINPSSGYTYYI 1FSG8 1FSG8 RSSQWIVQTNGNTYLH 1FSG8 VKCDR2 KVSSQFS VV()2012/130834 1F6G8 54 VKCDR3 FQGSHVPFT 1F6G8 55 VHCDR1 GYTFTHSGMN 2D2E3 56 VHCDR2 2D2E3 57 VHCDR3 SWWTDYFDY 2D2E3 58 VKCDR1 RSSQS:ViSNGNTYL 2D2F8 59 VKCDR2 KVSNQFS 2D2E3 “-2D2E3 FQGSiFPYT GYTFTWCYMH 27A9 ETNPRWGGTNYN 27A9 GTSGYIYFDY 27A9 RSSQS:VHS 27A9 KVSYQFS 27A9 “-27A9 FQGSiVPYT VHCDR1 5C GYTFTDYYMH PQWGGTTYN E.—FQASiVPYT SGPG LVAPSQRLS: TCTVSGFSLT SYIVDWVRQS PGKGL?WLGV "WAGGSTNYN SALRSRLSIT KSNS<SQVFL TDDT AIYYCASAAY YSYYNYDGFA YWGQGTLVTV DVVWTQTPLT LSVTHGQPAS "SCKSSQSLL {TYLYW QSP< RLIYLVSKLD SGVPDRFSGS DFTLK: SRVﬁAﬁDVG YYCLQSTHFP HTFGGGTKLt QVQLQQPGAI LVKPGASVKL SCKTSGYTFT NYWMiWVRQR W G1 TNPRNGGTNY <ATL TVDKSSNTAY MQLSSLTFG SAVYYCTIGT SGYDYFDYWG QGTTLTVSS 35E6VK i LPVSLGDQAS iSCQSSQTTV HSWGNTYL <PGQSP< LLIYKVSWRF SGVPDQFSGS GSGTGFTL I ﬁAﬁDLGV YFCFQASiFP YTFGGGTKLﬁ < 45BQVH QVQLKQSGPG LVAPSQSLST TCTVSGVSL TYDVDWVRQS PGKDLEWLGV MWSGGTTWYN SALKSRLNIW KDSS<SQVFL {MSGLQTDDT GLYYCATDRW YWGQ GTLVTVSA 45BQVK DVVMTQTPLT "SCQSSQSLL {TYLHW LLQRPGQSPK SGVPDRFSGS DFTLK: VV()2012/130834 U) W<1 . ZDLGV YYCLQST HTFGGGTKL¥ 76 48E1VH SGPG LVAPSQSLS: TCTVSGFSLT DWVRQS PGKGL?WLGV "WAGGSTWYN SALKSRL S {NQVFL RMNSLQTDDT AMYYCASDRW SPGGFAYWGQ Iiilllllllllllll48E1VK DVVWTQTPLT LSVTHGQPAS "SCKSSQSLL QSPK RLIHLVS<LD SGVPDRFSGS SQVﬁAiDLGV FYCLQTTiFP HTFGGGTKLt \l O) 49F8VH SLS: TCTVSGFSLS DWVRQS "WAGGSTTYW SAFKSQLSIS , {SQVFL {MNSLQTDDT AMYYCASERS GDSPFGYWGQ GTLVTVSA \lO 49F8VK DVVVTQSPL" LSVT GQPAS "SCKSSQSLL {TYLNW LLQ' ﬂ RT. HTIVS {TD SGVPDRFSGS DFTLK: SQVZ .DLGV YYCLQNSiFP {TFGSGTKLt 6A7F1VH LVRPGGSLKL SCAASGFTFS TYGMSWVRQS VTQGGNTYYP DSMQGRFTIS QDNVGNILYL A YS GWYFDVWGAG TTVTVSS O) _\ K IPLS LPVSLGDQAS :SCQSSQSIV {SNGDTFL YLQ<SGQSP LLIYKVSWRF SGVPDRFSGS GSGTDFTL " SRVﬁAﬁDLGV SQIP YTFGGGTKLt K O)N 3B4E7VH QVQLQQSGAI LARPGASVKM SC<ASGYTFT YYT:{WVKQR PGQGLﬁW GY NBASSYTNY IQ<FKDRATL TADKSSSTAY MQLSSLTS: SAVFYCAQGA NWDYFDYWGQ SS Iiilllllllllllll3B4E7VK DVLWTQTPLS LPVSLGDQAS :SCRSSQN <PGQSP< LLIYKVSWRF SGVPDQFSGS ﬁAlDLGV YYCFQGSiVP YTFGGGTNLt O)A 2F1E5VH 1 LKKPGﬁTVK {SSGFTLT NYGMWWVKQV :NTYTGEPTY iDFKGQFAF SLETSARTAY AATYFCA’ GTDYFDYWGQ GTTLTVSS 0) 0| K LAVSLGQRAT :SCRASESVD {PGQPP T."YT.AS\TT.'T. GVPARFSGSG 7 DDAATY QDPW TFGGGT<LZ 1F6G8VH 1 LKKPGﬁTV< NYGMNWVKQV :NTYTGEPTY SLETSARTAY AATYFCAQSA GTTLTVSS O) 1F6G8VK LPVSLGDQAS LLIYKVSSRF YYCFQGSiVP O) 2D2E3VH ﬁLKKPGﬁTV {ASGYT NWWK WINTNTGEP ZﬁENGRE AESLﬁASAWT HDTATYFCAR DYFDYW 2D2E3VK LPVSLGDQTS iSCQSSQS: 1TJ.YKVSNRF SGVPDRLSGS YYCFQGSHFP YTFGGGTKLﬁ 27A9VH QVQLQQPGAI LVKPGASVKL SCKASGYTFT NCYMiWVKQR PGQGLﬁW G1 TNPRNGGTNY NEKFKR<ATL TVNKYSSTAY MQLSSLTSE SAVYYCTIGT SGYEYFDYWG QGTTLTVSS 91 27A9VK NI-LWTQTPLG LPVGLGDQAG LGCRGGQGLV HGDGN YLZ QGP< VL__YKVGYRF GGVPDRFGGG GGGTYFTL L'ALDTIGV YFCFQGGHVP YTFGGGTKL. K QVQLVQSGA VKKPGASVKV SCKASGYTF VRQA PGQGLL'WMGZ TNPRNGGTTY NLKFKG<ATW TRDTGTGTAY QG.I TAVYYCTLGT DYWG QGTLVTVGG 93 IL QPAG IGCQGGQGI LL__YKVGYRF GGVPDRFGGG 1 .I YYCFQAGHVP YTFGQGTKLL 94 IL LGVTPGQPAG _GCRGGQGIV I YLZ VGYRF GGVPDRFGGG GGGTGFTL YYCFQAGLVP YTFGGGTKLL K 95 Cbne22 I LVAPGQRLG_I TCTVGGFGLT GYLVDWVRQG CmmeﬂCHC I. WAGGGTVYN GALRGRLG..T KGVG<GQVFL T I AGAAY YGYYNYDGFA YWGQGTLVTV GAAGT<GPGV G<GT GGGTAALGCL VKDYFPLPVT VGWNGGALTG GVHTFPAVLQ GGGLYGLGGV GLGT QTY__CVVVHK PGNTKVD<QV LP<GCDKTHT CPPCPAPLAA GGPGVFLFPP KPKDTLMLGR TPLVTCVVVD VGHL'DPL'VKE' VWYVDGVLVH NAKTKPQLLQ YNGTYQVVGV LTVLLQDWLV {CKVGN KALPAP L<T G<A<GQPRIL PQVYTLPPGQ PYPG D AVLWL'GNG QPILNVY<TTP I I LYGKLTVD<G QWQQGVVFGC GVWHLALHNL {GLGLGP GK Cbne22 DVVWTQTPLT LGVT._GQPAG LGCKGGQGLL YTVG<TYLYW dﬂmeﬂcLC LLQQPGQGPK RLI.YLVG<LD GGVPDRFGGG GGGTDFTLK GRVLALDVG GTLFP HTFGGGT<LL {QTVAAPGV P__ PPPGDLQL KGGTAGVVCL LNNFYPRLA< VQWKVDNALQ GGNGQLGVTL QDG<DGTYGL GGTLTLG<AD YL<HKVYACI VTHQGLGGPV T<GFVQGLC am RTVAAPGVh__ PPPGDLQLKG GTAGVVCLLV WKVDNALQGG \GQLGVTLQD GKDGTYGLGG LVT VT GFVRGLC hCFIDomam {GPGVFP LAPGG<GTGG GTAALGCLVK DYFPLPVTVG WNGGALTGGV TFPAVLQGG GLYGLGGVVT VPGGGLGTQT YLCVVVHKPG \TKVD<QVILP {GCDKTLTCP PCPAPLAAGG PPKP {DTLMLGRTP ILVTCVVVDVG {LDPL'VKE'VW DGVLVHNA {TKPQL'QYN GTYQVVGVLT VLLQDWLVG< {CKVGNKA LPAP L<T <A<GQPQLPQ VYTLPPGQLL {VQVGLTC YPGI AVLWLGVGQP LNVY<TTPPV DGDGGFFLY GKLTVD<GI QQGNVFGCGV WHLALHNLYT <GLGLGPG< HCVH5C QVQLVQGGAI VKKPGAGV GCKAGGYTFT DYYWHWVQQA PGQGLLWMG TNPRNGGTTY NLKFKGKATM TRDTGTGTAY MILTGGTIRGLD TAVYYCTLGT GGYDYFDYWG QGTLVTVGGA GTKGPGVFPL APGGKGTGGG TAALGCLVKD YFPLPVTVGW WSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY __CNVNHKPSN TKVDKKVLPK SC 100 LCVK18 D._VWTQTPLS LSVTPGQPAS ISCRSSQS_V HSDGW YLLW YLQ<PGQSPK LL._YKVSYRF SGVPDRFSGS GSGTDFTL< LDVGV YYCFQASHVP YTFGQGT<LL RTVAAPSV h'._b'PPSDLQL KSGTASVVCL LNNFYPRILA< V DNALQ SGNSQL'SVTL QDSKDSTYSL SSTLTLS<AD YI<HKVYACIL VTHQGLSSPV T<SFWRGILC 101 D.VWTQTPLS LSVTPGQPAS QSIV I YLLW YLQ<PGQSPK LL__Y<VSYRF SGVPDRFSGS {I SRVLALDVGV YYCFQASHVP YTFGGGT . SV h'._b'PPSDLQL KSGTASVVCL LNNFYPR DNALQ SGNSQLSVTL QDSKDSTYSL S I I<HKVYACL VTHQGLSSPV T<SFWRGLC The mouse monoclonal antibody clone 22 was tested for its ability to neutralize dabigatran anticoagulant activity in human plasma in the thrombin clotting time assay outlined in Example II. The antibody completely reversed the dabigatran-mediated prolongation of thrombin dependent clotting in human plasma in a dose dependent manner (Figure 5).

The antibody also effectively inhibited dabigatran function in human whole blood. A Fab ted from this antibody blocked dabigatran ty in human plasma demonstrating that monovalent antigen binding domains can neutralize compound agulant activity.

(Figure 6).

The major metabolic y of dabigatran in humans is through the glucuronidation of the carboxylate moiety. Dabigatran acylglucuronides have been shown to be pharmacologically active (Ebner et al., Drug Metab. Dispos. 2010, 38(9):1567-75). To test whether the mouse monoclonal antibody clone 22 could neutralize these metabolites, tran acylglucuronides were ed from the urine of rhesus monkeys treated with dabigatran and evalulated in the thrombin clotting time assay. The antibody dose dependently reversed the dabigatran acylglucuronide-mediated prolongation of thrombin dependent clotting in human plasma with r potency to that seen with dabigatran (Figure 7). Thus the dy is effective in blocking the anticoagulant activity of dabigatran metabolites found in humans.

The affinities of the Fab and the mouse-human chimeric antibodies comprising the le domains of clone 22 were determined using Kinexa logy. A constant concentration of Fab or ic antibody was incubated with various concentrations of tran until equilibrium was reached. After this incubation the concentration of free antibody was ined by ing the antibody on Neutravidin beads coupled with a Biotin-conjugated dabigatran analog. The captured Fab was detected with an anti-Mouse lgG (Fab specific) F(ab')2 fragment d with FITC. The captured chimeric antibodies were detected with an anti-human lgG conjugated with Cy5. The dissociation constants were calculated using a 1:1 g model. The results from these experiments are summarized in the table below. 1O Affinity of anti-dabigatran antibodies Antibody Apparent Kd Clone 22 Fab 48 pM Clone 22 Chimeric Ab 34 pM Both the Fab and the chimeric antibodies bind dabigatran with high affinity.

Thrombin clotting time assay Briefly human plasma is obtained by taking whole blood into 3.13% sodium citrate. This is then centrifuged to obtain platelet free plasma and transferred to a separate tube and frozen until required on the day of the assay. Plasma is thawed at 37°C on the day of the assay.

The thrombin clotting time is performed as follows. First in is diluted to manufacturer’s ication (3 lU/mL thrombin) in the buffer provided (Dade Behring Test kit) and prewarmed to 37°C. It is used within 2 hrs of being prepared. All assays were performed on a commercially available CL4 clotting machine (Behnk Electronics, Norderstadt, Germany). Fifty uL of plasma is pipetted into ed cuvettes with a magnetic stirrer and allowed to stir for 2 min in the well preheated to 37°C in the CL4 machine. At this point 100 uL of the thrombin solution is added and the time required for the plasma sample to clot is ed automatically by the CL4. Dabigatran is preincubated for 5 min in plasma in the provided cuvettes, before adding thrombin and starting the measurement. lf antibody is also tested (up 50 uL of stock solution), there is a further 5 minute incubation at 37°C before beginning clotting (Le. 10 min total incubation with tran, 5 min total incubation with antibody and then clotting is initiated with thrombin).

Activity of chimeric antibodies and humanized Fabs in the thrombin time assay is shown in Figures 8 -10, respectively.

Affinity determinations (Kinexa Method) The ties of Fab and mouse-human chimeric antibodies were ined using KinExA® logy. A constant concentration of Fab or chimeric antibody was incubated with various concentrations of dabigatran until equilibrium was reached. After this incubation the concentration of free antibody was determined by capturing the dy on Neutravidin beads coupled with a Biotin-conjugated dabigatran analog. The captured Fab was detected with an anti-human lgG (Fab specific) F(ab')2 fragment labeled with FITC.

The captured chimeric antibodies were detected with an anti-human lgG conjugated with Cy5. The dissociation constants (KD) were calculated using a 1:1 binding model.

To measure rate constants (kon and koff) with the ® instrument, the Kinetics Direct method was used. In this method, the binding partners are mixed in solution, and the concentration of free active binding sites is probed over time as active g sites are depleted due to the formation of complexes. Data points are collected at specified time intervals and the signals are analyzed. In this way, kon is measured ly and the off- rate koff is calculated as koff = KD x kon.

Table: KD values of chimeric antibodies determined using KinExA® technology.

Chimeric Ab KD (pM) Table: KD , kon and koff of humanized Fabs VH5C/VK18 and VH5C/VK21 H5C/VK18 133 pM 9.38e+005/Ms 1.25e-004 /s H5C/VK21 147 pM 1.377e+006/Ms .029-004 /s Fab-dabigatran complex ion and crystallization The Fabs were concentrated to 10 mg/ml, mixed with a 2 molar excess of dabigatran and incubated for 1 h at 4 °C. x and crystallization on were mixed 1:1. The complex crystallizes in 25 % PEG 1500, 0.1 M SPG buffer (pH7).

Data collection and structure ination Datasets for all crystals were collected on the Swiss light Source beamline PXI - X06SA of the Paul Scherrer Institut. All datasets were processed with the autoPROC package (Vonrhein, C., Flensburg, C., Keller, P., Sharff, A., Smart, 0., Paciorek, W., Womack, T. & Bricogne, G. (2011). Data sing and analysis with the autoPROC toolbox. Acta Cryst. D67, 293-302.).

Fab VH5C/VK21:Dabigatran ls grew in space group P212121 with unit cell dimensions a=59.97 A, b=78.39 A, C: 87,67 A and diffract to 2.2 A resolution. The complex structure was solved by molecular replacement with the program phaser (Collaborative Computational Project, number 4. 1994. "The CCP4 Suite: Programs for Protein Crystallography". Acta Cryst. D50, 760-763. Phaser crystallographic software.

McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. J. Appl.

Cryst. (2007). 40, 658-674.) using a homologous Fab structure D 1C1 E) as the starting search model. Analysis of the electron density map showed clear electron y for dabigatran. The te structure was improved with multiple rounds of model building with Coot and refinement with autoBUSTER (Coot: model-building tools for molecular graphics" Emsley P, Cowtan K Acta Crystallographica Section D-Biologica/ Crystallography 60: 2126-2132 Part 12 Sp. lss. 1 DEC 2004. Bricogne G., Blanc E., 2012/055397 Brandl M., Flensburg C., Keller P., Paciorek W., Roversi P, Sharff A., Smart O.S., Vonrhein C., Womack TO. (2011). BUSTER version 2.11.2. Cambridge, United Kingdom: Global Phasing Ltd).

Fab VH5C/VK18:Dabigatran crystals grew in space group P21 and P212121, tively.

Crystals with space group P21 showed unit cell dimensions of a=51.81 A, b=128.92 A, c= 60.26 A and ct to 1.9 A resolution. Crystals with space group P212121 showed unit cell dimensions of a=48.20 A, b=59.74 A, c= 127.69 A and diffract to 2.2 A resolution.

Both complex structures were solved by molecular replacement with the program phaser 1O using the structure of Fab VH5C/VK21 as the starting search model. Analysis of the electron density maps showed clear on density for dabigatran. The complete structures were improved with multiple rounds of model building with Coot and refinement with autoBUSTER.

In silico analysis of Spatial Aggregation Propensity (SAP) The spatial aggregation sities (SAP) for each atom and each residue was calculated as described in (1) with the exception that e hydrophobicity parameters where taken from (2). The Fv SAP is calculated as the sum over all positive residue SAP values in the variable domains of the antibody. The CDR SAP is calculated as the sum over all positive residue SAP values in the complementary determining regions of the antibody. Fv SAP and CDR SAP have been calculated for 850 different antibody structures from the n data bank (PDB), yielding a mean (HPV and uch) and standard deviation values (on and 0ch ) for both properties.

Z-scores for the Fv SAP and CDR SAP for the antibodies where then ated according Z-score(Fv SAP) = ( Fv SAP - uF\,)/oFV and Z-score(CDR SAP) = ( CDR SAP - uCDR)/OCDR.

Results (Figure 11): Humanized Fab 18/15: Z-score(Fv SAP) = 1.06 Z-score(CDR SAP) = 1.00 Humanized Fab VH5C/VK18: Z-score(Fv SAP) = -0.61 Z-score(CDR SAP) = -0.84 Humanized Fab VH5C/VK21: Z-score(Fv SAP) = -0.61 e(CDR SAP) = -0.78 Fab 18/15 (see W02011089183) has more solvent-exposed hydrophobic surface than the average of known antibodies in the n data bank.

Surprisingly, both VH5C/VK18 (SEQ ID NO: 99/SEQ ID NO: 100) and VH5C/VK21 comprises SEQ ID NO: 99/SEQ ID NO: 101) have less solvent-exposed hydrophobic surface than the average of known antibodies in the protein data bank ive Z- scores). This means that these compounds have an increased solubility in s media and a lower tendency for ation, making them more suitable for stable drug formulations with high antibody concentrations. (1) Chennamsetty et. al., Proc Natl Acad Sci; 2009, 106(29), pg 11937-11942 (2) Cowan and Whittaker, Pept Res; 1990, 3(2), pg 75-80 Expression of Fab in CHO cells Fabs were produced by transient transfection into CHO DG44 cells and subsequent selection and generation of stable cell pools. Figure 13 shows the titers of fed batch runs with Fab 18/15 (see W02011089183), Fab VH5c/Vk18 and Fab VH5c/Vk21. Surprisingly, Fabs VH5c/Vk18 and VH5c/Vk21 show 5-10 fold higher titers as compared to Fab 18/15.

I

Claims

WE CLAIM:

1. An antibody molecule against dabigatran comprising a heavy chain variable domain with a CDR1 of SEQ ID NO: 67, a CDR2 of SEQ ID NO: 68, and a CDR3 of SEQ ID NO: 9, and a light chain variable domain with a CDR1 of SEQ ID NO: 64, a CDR2 of SEQ ID NO: 65, and a CDR3 of SEQ ID NO: 69.

2. The antibody molecule of claim 1 comprising a heavy chain of SEQ ID NO: 99, and a light chain of SEQ ID No: 100.

3. The antibody le of claim 1 comprising a heavy chain of SEQ ID NO: 99, and a light chain of SEQ ID No: 101.

4. The antibody molecule of claim 1 which is a monoclonal antibody, a human antibody, a humanized dy, a chimeric antibody, a fragment of an dy, or a single chain antibody,.

5. The antibody molecule of claim 4, wherein said fragment of an antibody is a Fab, Fab’, or F(ab’)2 fragment.

6. The antibody molecule of claim 4, wherein the single chain antibody is a single chain variable fragment (scFv).

7. Use of an antibody molecule of any one of the preceding claims 1 to 6 for the manufacture of a medicament for the therapy or prevention of side effects of agulant therapy, and/or for reversal of an overdosing of an anticoagulant.

8. The use of claim 7, wherein the side effect is a bleeding event.

9. A method of manufacturing an antibody molecule of any one of claims 1 to 6, sing (a) providing a host cell comprising one or more nucleic acids encoding said antibody le in functional association with an expression control sequence, (b) cultivating said host cell, and AH26(10039265_1):JIN (c) recovering the dy molecule from the cell culture, wherein the host cell is not within a human.

10. A kit comprising an antibody of any one of claims 1 to 6, or a pharmaceutical composition thereof.

11. A kit comprising: (a) an antibody of any one of claims 1 to 6, or a ceutical composition thereof; (b) a ner; and (c) a label.

12. A kit comprising an antibody of any one of claims 1 to 6, and dabigatran, dabigatran etexilate, a prodrug of dabigatran or a pharmaceutically acceptable salt thereof. Boehringer Ingelheim International GmbH By the Attorneys for the Applicant SPRUSON & FERGUSON Per: AH26(10039265_1):JIN